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Genetic variations within loci encoding cell surface receptors of the innate immune system, such as 
Complement Receptor 3 (CR3) and Fc gamma Receptors (FcγRs), are strongly associated with 
Systemic Lupus Erythematosus (SLE). Such genetic associations implicate the functional importance 
of these receptors in disease pathogenesis. 
 
CR3 (also known as CD18/CD11b) is an integrin receptor found on multiple immune cell types, 
including monocytes/macrophages, neutrophils, and Natural Killer (NK) cells. CR3 is a promiscuous 
receptor with many natural ligands, including complement fraction iC3b, ICAM-1, and β-glucan, and 
functions as a phagocytic receptor, leukocyte adhesion molecule, and immune regulator. ITGAM 
encodes the α-chain (CD11b) of CR3, and a common polymorphism (rs1143679) within ITGAM, 
which results in a non-synonymous amino acid substitution (R77H) in CD11b, is robustly associated 
with SLE (OR=1.76).  
 
In this thesis I demonstrate that the SLE-associated R77H common polymorphism does not affect 
the cell surface expression of CR3 on ex vivo monocytes and neutrophils in a healthy cohort of 
European ancestry. Additionally, a collaborative resequencing project identified two case-specific 
non-synonymous coding variants in ITGAM, which I demonstrate result in the under-functioning of 
CR3-mediated phagocytosis using an in vitro model. Finally, using a CR3-specific small molecule 
drug, which has therapeutic potential in inflammatory disease, I observed a CR3-dependent 
significant reduction in STAT5 phosphorylation following NK cell activation with cytokines.  
 
There are two genetic variants found within the FCGR locus on chromosome 1 which are robustly 
associated with SLE; homozygosity of the I232T (rs1050501) polymorphism within FcγRIIb (FCGR2B), 
and decreased gene copy number of FCGR3B. Recent work demonstrated that a consequence of a 
deletion at the FCGR locus, spanning the entire FCGR3B gene and parts of the upstream FCGR2C and 
downstream FCGR2B genes, results in ectopic expression of FcγRIIb on NK cells. In this thesis I 
explored the possibility of a genetic interaction between the two – copy number variation (FCGR3B) 
and rs1050501 (FCGR2B) - SLE-associated variants, but failed to detect such an effect within the 
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Chapter 1: Introduction 
 
1.1 Systemic Lupus Erythematosus 
1.1.1 Overview 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of 
symptoms and wide range of severity resulting from the breakdown of immune tolerance. It can 
affect any organ system of the body due to its characteristic presence of autoantibodies to nuclear 
components (antinuclear antibodies (ANA)), including anti-double-stranded DNA (dsDNA) (Borg et al. 
1990). However, there is no single clinical or immunological feature required for diagnosis: disease 
diagnosis is dependent on the presence of at least four of the diverse range of pathologies listed in 
the American College of Rheumatology (ACR) 1982 classification criteria (Tan et al. 1982), in any 
combination, making SLE a very heterogeneous disorder. Clinical features include fatigue, skin 
rashes, neurological complications, arthritis, and glomerulonephritis, as a result of tissue damage 
following immune complex deposition and subsequent local inflammation. Despite significant 
improvements in recent decades, SLE is still associated with increased morbidity and decreased life 
expectancy (O’Neill and Cervera 2010). 
 
Two of the cellular characteristics of SLE are impaired clearance of apoptotic cells by phagocytes 
(Herrmann et al. 1998; Gaipl et al. 2007), and B cell auto-reactivity (Rahman 2004), highlighting the 
involvement of both innate and adaptive immune systems, respectively, in disease pathology. The 
work in this thesis focuses on the role of the innate immune system in SLE, and the effects of genetic 
variants in genes encoding receptors on the surface of innate immune cells. 
 
1.1.2 Innate Immune dysfunction in SLE: The ‘waste disposal’ hypothesis 
 
In addition to recognising and destroying invading pathogens during the inflammatory response, the 
phagocytic cells of the innate immune system – neutrophils, macrophages – recognise apoptotic 
cells and rapidly dispose of them to avoid an inflammatory response (Abbas, Lichtmann 2012; 
Hochreiter-Hufford and Ravichandran 2013). Apoptosis is the programmed cell death triggered by 
multiple stimuli, including infection and damage due to cytotoxic environmental exposure (such as 
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UV radiation). Apoptotic cells are opsonised with soluble ligands of phagocytic receptors, such as 
complement factors, enabling their effective recognition (Pittoni and Valesini 2002). The ‘waste 
disposal’ hypothesis is a central paradigm of SLE disease biology, and refers to the under-functioning 
of apoptotic clearance by phagocytes (Gaipl et al. 2007; Pittoni and Valesini 2002; Herrmann et al. 
1998). Defective clearance of apoptotic cells leads to their accumulation and subsequent release of 
nuclear components. Through presentation by antigen-presenting cells (APCs), such as dendritic cells 
(DCs), and exposure to cells of the adaptive immune system, this leads to the production of the 
characteristic autoantibodies to nuclear components (Kelley et al. 2010). Genetic variants in genes 
encoding phagocytic receptors, such as ITGAM, which encodes the α-chain of complement receptor 
3 (CR3), are among the strongest risk factors for SLE, adding further support to this paradigm of 
disrupted ‘waste disposal’ (Fagerholm et al. 2013). 
 
Interferon (IFN) is a potent anti-viral defence mechanism of the innate immune system, primarily 
produced by plasmacytoid dendritic cells (pDC) in response to viral antigens. However, there is a 
known ‘IFN signature’ in SLE patients, where serum levels of IFN-α – part of the type I interferon 
family -  are elevated and IFN-responsive genes are upregulated, and this is further correlated with 
disease severity (Baechler et al. 2003). Type I interferon can stimulate the maturation of monocytes 
into activated DCs, and also the differentiation of B cells into antibody-producing plasma cells (Jego 
et al. 2003). It is thought that autoantigens and autoantibody-containing immune complexes (ICs) in 
SLE patients stimulate the production of IFN, which in turn drives autoantigen presentation and 
autoantibody production, in a positive feedback loop that propagates disease (Baechler, Gregersen, 
and Behrens 2004).  
 
Several studies have revealed substantial amounts of DNA fragments circulating in the plasma of SLE 
patients, which is furthermore associated with disease activity, and the circulating DNA fragments 
have lower methylation levels (Sato et al. 1999; Lövgren et al. 2004). Apoptotic DNA, but not 
necrotic DNA, has been shown to induce anti-dsDNA antibodies (Abs) in BALB/c non-SLE prone mice, 
which lead to severe glomerular deposits of immunoglobulin G (IgG) antibodies (Wen et al. 2007). 
The methylation of apoptotic DNA is lower than necrotic DNA, and the hypomethylated status of 
apoptotic DNA was demonstrated to be a key, but not exclusive, factor in the induction of the SLE-
like symptoms in healthy mice: up-methylation of apoptotic DNA impairs, but does not abolish, its 
ability to induce auto-Abs; de-methylation of necrotic or normal DNA enabled it to induce auto-Abs 
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(Wen et al. 2007). Indeed, the contribution of epigenetic changes to autoimmunity is actively being 
explored (Ballestar 2011) and DNA methylation state has been shown to contribute to SLE 
discordance in monozygotic twins (discussed below 1.1.3) (Javierre et al. 2010).  
 
Additionally, increased rates of apoptosis have been observed in lymphocytes of SLE patients. Such 
apoptotic dysfunction could also increase the exposure of nuclear antigens leading to ANAs. 
However, the presence of autoantibodies is not sufficient for disease onset, as these are found in ~5 
of healthy individuals and are associated with ageing (Niederer et al. 2010a). It is the presence of 
autoantibodies, particularly ANAs, together with reduced ability to clear autoantibody-containing ICs 
by phagocytes, followed by inappropriate inflammatory response to deposited ICs that contribute to 
SLE pathogenesis (Gaipl et al. 2007). Low-affinity Fcγ receptors (FcγRs), which bind the Fc domain of 
IgG molecules, are encoded within the FCGR locus on chromosome 1q23.3. Multiple genetic 
associations across this locus implicate the under-functioning of FcγRs in SLE pathogenesis, adding 
further support to defective autoantibody IC clearance in disease biology (Niederer et al. 2010a).  
 
1.1.3 Epidemiology and the evidence for a genetic contribution 
 
There is a striking sex difference in SLE prevalence; 90% of cases are female. Furthermore, the child-
bearing years between puberty and menopause harbour the greatest risk of disease onset, strongly 
suggesting an important hormonal role in SLE (O’Neill and Cervera 2010). However, an X 
chromosome gene-dose effect may also contribute to the observed sex imbalance. Indeed, the 
prevalence of SLE in males with Klinefelter’s syndrome (47, XXY) is significantly greater than in 46, XY 
males, and approaches that of (46, XX) females (Scofield et al. 2008). 
  
There are also population differences in SLE risk. The disease is distributed unevenly across the 
globe, and there are known variations in prevalence across ancestral populations (Shapira, Agmon-
Levin, and Shoenfeld 2010). Such population-specific variance is observed within the same 
geographical area, suggesting these differences are attributable to genetic factors as opposed to 
environmental differences. For instance, Amerindians and African-Americans have greater disease 
susceptibility compared with European Americans (Shapira, Agmon-Levin, and Shoenfeld 2010). The 
population-specific differences are quite remarkable; a study in Birmingham, UK, reported a 
prevalence of 1:500 in Afro-Caribbean females, 1:1000 for South East Asian females, and 1:2500 for 
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White British females (Smith and Gordon 2010). Furthermore, ancestral groups with increased 
prevalence also exhibit younger median age of disease onset and increased disease severity 
(Shapira, Agmon-Levin, and Shoenfeld 2010). However, in addition to genetic ancestry, socio-
economic factors have also been shown to influence SLE outcome, although their contribution to 
disease onset has yet to be explored (Sutcliffe et al. 1999).  
 
The contribution of genetic factors to SLE susceptibility is further supported by familial aggregation 
of disease and increased concordance rate between monozygotic (MZ) twins compared with 
dizygotic (DZ) twins and full siblings: 24-57% and 2-5%, respectively (Deapen et al. 1992; Bogdanos 
et al. 2012; Alarcón-Segovia et al. 2005). SLE discordance between monozygotic twins suggests that 
factors aside from variation of genetic sequence contribute to disease susceptibility; it is important 
to differentiate sequence variation from epigenetic changes here as there is growing evidence that 
epigenetic factors contribute to twin discordance (Javierre et al. 2010). Despite this, the study of the 
inherited ‘fixed’ genetic variants contributing to SLE risk will ultimately aid our understanding of the 
immunological mechanisms contributing to disease onset (Rhodes and Vyse 2008). Immunological 
dysfunction pre-dates the clinical manifestations of SLE, which presents a problem of establishing 
phenotypic disease paradigms of cause and effect (Arbuckle et al. 2003). Genetic variations that are 
associated with disease risk, on the other hand, are not affected by disease progression. 
Furthermore, their effects on cellular functions can be studied in isolation of disease using ex vivo 
cells from healthy individuals or in vitro models, aiding the understanding of immune dysfunction 
leading to disease onset. Ultimately, understanding these underlying mechanisms will hopefully aid 
the development of targeted therapeutics.  
 
In addition to the role of hormones in SLE risk, as discussed above, a number of known 
environmental factors have been shown to contribute to SLE susceptibility, such as infectious agents 
(e.g. Epstein-Barr Virus (EBV)), diet, and chemicals (Gourley and Miller 2007). Environmental 
conditions interact with DNA by means of epigenetic modifications, which are cell- and tissue-type 
specific, in both normal and pathological individuals. Epigenetic changes, although reversible, are 
not necessarily altered/lost during mitosis, or even meiosis (Bird 2007). Both methylation and 
histone post-transcriptional modifications affect gene expression, which in turn affect protein 




1.2 The Genetics of complex diseases 
 
The past 10 years has seen great technological advancements, which have aided the identification of 
genetic variants contributing to complex disease onset (Rhodes and Vyse 2008). These variants 
range in size from single nucleotide polymorphisms (SNPs) to copy number variations (CNV) of large 
segments of DNA, and typically contribute modest effect size on disease risk (Moser et al. 2009).  
 
1.2.1 GWAS and the Common Disease-Common Variant hypothesis 
 
Under the common disease-common variant (CDCV) hypothesis, genetic variants, which are not 
disease-specific but present throughout the population, confer modest contribution to disease risk. 
However, given their contribution to disease onset, these variants will be present at significantly 
higher frequencies in disease cohorts. It is the accumulation of such variants, perhaps in concert 
with environmental triggers, which may ultimately lead to diseased onset in the ‘threshold liability 
model’ (Becker 2004; Wandstrat and Wakeland 2001). Genome-wide association studies (GWAS), a 
‘hypothesis-free’ approach where the frequencies of hundreds of thousands of SNPs across the 
genome are compared between large cohorts of cases and controls, has uncovered a plethora of 
common alleles with modest effect sizes (odds ratios (OR)<2) associated with complex diseases, 
under the CDCV hypothesis. There are currently 52 genetic loci known to be independently 
associated with SLE - the vast majority of which are products of the genome-wide technological 
advancements of recent years – and the genetic variation within these loci is estimated to account 
for 15-20% of the total additive genetic variance (Harley et al. 2008; Moser et al. 2009), [J. Bentham, 
D. L. Morris, et al. 2014, manuscript in submission].  
 
Under the CDCV hypothesis, the majority of the heritability of common diseases was predicted to be 
attributable to common genetic variants. Therefore, GWA studies were expected to explain the 
majority of the genetic variance (Reich and Lander 2001). This certainly isn’t the case for most 
complex diseases, as with SLE, and the amount of remaining unexplained genetic variance (the so 
called ‘missing heritability’, discussed below) following very large GWA studies is higher than initially 
anticipated (Manolio et al. 2009; Eichler et al. 2010; So et al. 2011). However, GWAS has been 
successful in highlighting the involvement of previously unknown genes/pathways in disease 
22 
 
susceptibility and has provided the foundation for future work, such as resequencing projects 
searching for rare variants within known disease-associated loci (discussed in 1.2.2). 
 
1.2.2 Rare variants  
 
Rare variants with larger effect sizes (OR≥2), but present at frequencies that fall below the 
detectable threshold of most GWA studies (<5%), have been hypothesised to explain part of the 
‘missing’ genetic effect of complex diseases (Pritchard 2001; Pritchard and Cox 2002). Although 
these variants are individually rare, they are collectively common, therefore may make a significant 
contribution to disease risk on the population level.  
 
However, due to their low minor allele frequency (MAF) and incomplete penetrance, individual rare 
variants may never reach statistically significant levels of association, irrespective of very large 
sample sizes (Heinzen et al. 2012). Furthermore the relatively high de novo mutation rate in humans 
means chromosomes of unaffected individuals will also harbour rare, or even private, mutations that 
may or may not influence disease risk (Keinan and Clark 2012). Coupled with the expansion of the 
human population growth in recent history, this has resulted in an excess of rare variants within our 
genomes (Keinan and Clark 2012). Genome- or exome-wide sequencing may therefore uncover 
many new variants, but determining which of these are functionally relevant to disease is not easy 
by genetic analysis alone (Cooper and Shendure 2011).  
 
One approach is to use the notable common variant discoveries of GWAS to focus on resequencing 
candidate genes that are already known to contain common disease risk variants. Indeed, many 
studies have now successfully identified additional rare variants in GWAS-associated loci (Torgerson 
et al. 2012; Rivas et al. 2011). However, the largest of such studies focused on the coding exons of 25 
autoimmune GWAS-associated loci and concluded that there was a negligible affect from rare 
variants in these loci (Hunt et al. 2013).  
 
The optimal analysis of rare variants is still an area of high debate, and various methodologies have 
been suggested (Madsen and Browning 2009; B. Li and Leal 2008; D.-Y. Lin and Tang 2011). Some 
methods involve weighting which rely on computational predictions of functional effects (Price et al. 
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2010). As of yet, there has been no unified agreement on the best genetic methodology for rare 
variant analysis, and issues regarding the robustness of case-control approaches – which are often 
used for common variant associations - are being addressed (Cheng and Chen 2013).  
 
Ultimately, it is functional analyses of individual rare variants that will best enable us to understand 
their importance in disease pathogenesis. Furthermore, by resequencing disease-associated loci, the 
functional analysis of rare variants will add confirmatory evidence to disease biology paradigms 
established by the functional effect of common variants. Chapter 4 of this thesis explores the 
contribution of rare variants within the SLE susceptibility gene ITGAM to disease pathogenesis. 
 
1.2.3 Copy Number Variation 
 
Copy number variation (CNV) is the name given to the phenomenon that segments of DNA, ranging 
from kilobases (Kb) to megabases (Mb), can diverge from a diploid number of two copies present in 
an individual genome. CNV is not a rare occurrence in the human genome and is thought to make a 
substantial contribution to phenotypic variation (Schaschl, Aitman, and Vyse 2009). There is a great 
deal of inter-population variation in the frequency of CNV, and indeed the range of observed copies 
(Hardwick et al. 2011; Molokhia et al. 2011).  
 
Some copy number variable loci have been associated with disease susceptibility (Olsson and 
Holmdahl 2012), including low copy number (CN) of FCGR3B with SLE susceptibility (discussed in 
1.7.2) and increased CN of DEFB genes with Psoriasis susceptibility (Willcocks et al. 2008; Hollox et 
al. 2008). This type of variation is often missed in genome-wide association studies due to low 
linkage disequilibrium (LD) between CNV and common SNPs, or regions of such complexity are 
excluded from such studies, and it has been postulated that CNV could contribute to the 
unexplained genetic risk of complex diseases (Eichler et al. 2010). However, a large genome-wide 
survey concluded that it was unlikely for common CNV alone to explain much of the ‘missing 
heritability’ (Conrad et al. 2010). Interestingly this study also suggested that, in the presence of high 





1.2.4 Genetic Interactions 
 
The paradigm of ‘missing heritability’ in recent years has focused on as-of-yet unidentified genetic 
variants that, once identified, are expected to increase the amount of narrow-sense (additive) 
heritability of complex diseases. However, this paradigm assumes an additive model of contribution 
for each genetic variant, both known and unknown (Zuk et al. 2012). Without fully exploring the 
possibility of epistasis between associated genetic variants, whereby the combined effect of two risk 
factors is greater than the sum of the effects of the individual variants, we may be underestimating 
the amount of heritability currently explained (Eichler et al. 2010). In which case, at least part of 
what is currently considered as ‘missing heritability’ could in fact be ‘phantom heritability’ due to the 
assumption that heritability of complex diseases is largely additive (Zuk et al. 2012). Therefore, 
exploring the possibility of genetic interactions is of key and current importance within complex 
disease genetics.  
 
Indeed, gene-gene interactions between associated SNPs in SLE have been successfully identified in 
recent years (X. Zhou et al. 2012; Hughes et al. 2012; Leng et al. 2012; Zuo et al. 2014). In one study, 
a candidate gene approach was employed; five genes – BLK, TNFSF4, TRAF1, TNFAIP3, and REL – all 
known to be involved in B cell and T cell signalling, were chosen for interaction analyses in Chinese 
and European populations. The study was successful in providing evidence for gene-gene 
interactions, in particular between BLK and TNFSF4  (X. Zhou et al. 2012). Similarly, another study 
chose two SLE-associated genes, BLK and BANK1, involved in B cell signalling and successfully 
demonstrated a gene-gene interaction between them, and, furthermore, demonstrated a functional 
interaction between the two protein products, BLK and BANK1 (Castillejo-López et al. 2012). With 
evidence supporting complex disease associations across an increasing number of loci, hypothesis-
free searches for genetic interactions are unlikely to be fruitful due to multiple-testing restrictions. 
Thus, hypotheses derived from common pathways and/or protein-protein interactions can aid the 
discovery of gene-gene interactions (Sun and Kardia 2010). 
 
I explore the possibility of a hypothesis-based genetic interaction between the FCGR2B-I232T SNP 





1.2.5 Sub-phenotype analyses 
 
As discussed above, SLE is a very heterogeneous disorder. Recently, efforts have been made to 
dissect the genetic associations contributing to various sub-phenotypes, such as the presence of 
anti-dsDNA autoantibodies, and lupus nephritis (Bolin et al. 2013; Kim-Howard et al. 2010; Chung et 
al. 2011). In such analyses, some variants known to be associated with SLE no longer pass 
significance thresholds, suggesting they may contribute to specific clinical features. Although, 
reduced sample sizes following sub-phenotype stratification perhaps presents a problem for 
significant associations; particularly with less common subphenotypes (e.g. only ~5% of SLE cases are 
ANA negative). However, phenotypic homogeneity within the case cohort will be beneficial to 
delineating genetic variants contributing to specific immunological abnormalities. 
 
1.2.6 Overlap with other autoimmune diseases 
 
The comparison of GWA studies between autoimmune diseases has revealed some overlap in the 
loci conferring genetic susceptibility (e.g. BLK, TNIP1, TNFAIP3), suggesting variants within these loci 
contribute to general immune dysfunction as opposed to disease-specific phenotypes (Zenewicz et 
al. 2010). Although, there is growing evidence that this overlap in genetic susceptibility is limited 
(Ramos et al. 2011). The paradigm that specific genetic variants cause particular dysfunctions and 
collections of such variants lead to SLE onset is interesting, and support for such notions can 
sometimes be drawn from other diseases. As discussed above in section 1.1.2, there is a known ‘IFN 
signature’ in SLE patients (Baechler, Gregersen, and Behrens 2004). Gain-of-function variants of the 
SLE-susceptibility gene IFIH1 are associated with elevated IFN responses in interferonopathies, such 
as Aicardi-Goutières syndrome (Rice et al. 2014; Robinson et al. 2011).  
 
1.3 ITGAM  
1.3.1 Association with SLE 
 
Following a genome-wide linkage study, suggesting chromosomal position 16p12.3-q12.2 harboured 
SLE risk (Lee and Nath 2005), a candidate-gene approach then identified variation in ITGAM 
(16p11.2), as the causative association in a European population (Nath et al. 2008). Furthermore, by 
using two cohorts of African ancestry, in which the linkage disequilibrium (LD) across ITGAM, as with 
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all other genomic regions, is weaker, the minor allele (A) of the non-synonymous single nucleotide 
polymorphism (SNP) rs1143679 was isolated as the causal variant (Nath et al. 2008). Additionally, 
the association between SLE and 16p11.22 was independently identified in a GWA study (Hom et al. 
2008). The association with the minor allele of rs1143679 was further validated in independent 
cohorts of European and Hispanic ancestry (Pmeta = 7.1 x 10
-50, OR = 1.83) but the SNP was found to 
be largely monomorphic (ancestral ‘G’ allele only) in Korean and Japanese cohorts (S. Han et al. 
2009). A study in Hong Kong Chinese and Thai populations however, confirmed the same risk allele 
with disease association and furthermore with renal nephritis in SLE cases (W. Yang et al. 2009). This 
study also suggested a secondary independent association with rs1143683 (A858V) within ITGAM; 
the potential contribution of this polymorphism to SLE is addressed in Chapter 4. Recently a meta-
analysis of 12,155 cases and 14,300 controls from ethnically diverse populations including European, 
African American, Latin American, East Asian, and South Asian, demonstrated a robust association 
between rs1143679 and SLE (OR=1.76; 3.6 x10-90; Maiti et al. 2014). The MAF of rs1143679 is 
estimated to be ≈0.15-0.2 in SLE cases across multiple ethnicities (S. Han et al. 2009). 
 
ITGAM encodes the CD11b polypeptide, which non-covalently pairs with CD18 (encoded by ITGB2) 
to form complement receptor 3 (CR3; discussed in detail in section 1.4). The rs1143679 
polymorphism results in an arginine (R) to histidine (H) substitution at codon 77 (R77H) of CD11b. 
The R77H variant is located in the β-propeller domain of CD11b, which is not thought to be a direct 
binding site for any of the known CR3 ligands. However, as this transmembrane protein carries cell 
signals and, in doing so, alters its conformation, the R77H variation could affect the protein’s cell 
signalling leading to impaired function. In light of SLE pathologies, several CR3 functions could 
contribute to disease onset, in particular the diminished processing of iC3b-opsonised apoptotic 
cells.  
 
1.3.2 Association with SLE sub-phenotypes 
 
Clinical sub-phenotype analyses in a European cohort identified a strong correlation between 
rs1143679 and renal disease, discoid rash and immunological manifestations (Kim-Howard et al. 
2010). Also, a genome-wide association study with SLE cases stratified for anti-dsDNA autoantibody 
production – a clinically important sub-phenotype - found ITGAM to be more strongly associated 
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with anti-dsDNA positive SLE (OR=1.8; p=1.1 x10-15) than anti-dsDNA negative SLE (OR=1.3; p=2.1 
x10-4) (Chung et al. 2011).  
 
1.3.3 Association with other autoimmune diseases 
 
There is some overlap between the genetic associations of SLE and other autoimmune diseases, such 
as variations in BLK, TNIP1 and PRDM (Zenewicz et al. 2010; Ramos et al. 2011). Large case-control 
studies have reported associations between rs1143679 and Sjogren’s syndrome (OR=1.12; Pmeta= 
0.008), and systemic sclerosis (OR=1.12; Pmeta= 0.019), although these are very modest in 
comparison to the association seen with SLE (Anaya et al. 2011; Carmona et al. 2011). No association 
was found with multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, celiac disease, 
and type-1 diabetes (Anaya et al. 2011; Phipps-Green et al. 2009). Variation within ITGAM does not 
appear to confer susceptibility to general autoimmunity, but instead is thought to be largely SLE-
specific. 
 
1.4 Complement Receptor 3 
1.4.1 Overview 
 
ITGAM encodes CD11b/αm (165KDa), which binds non-covalently with CD18/β2 (95KDa) to form the 
heterodimeric cell surface receptor known as complement receptor 3 (CR3), also known as 
CD18/CD11b, αmβ2, and macrophage receptor-1 (Mac-1). CR3 is one of four members of the B2-
integrin family, which are possessed by all vertebrates and exclusively expressed on leukocytes 
(Hynes 2002). In addition to CD11b, CD18 can pair with CD11a (forming LFA-1; αLβ2), CD11c (forming 
CR4; αXβ2), and CD11d (forming αDβ2). Complete CD18 (β2) deficiency results in a rare and often fatal 
inherited disease known as Leukocyte adhesion-molecule deficiency disorder (LAD) (Shaw et al. 
2001). This life-threatening disorder highlights the importance of the β2-integrin family to the innate 
immune system.  
 
1.4.2 Expression profile and conformational states 
 
CR3 is mainly expressed on cells of the innate immune system - phagocytic cells (neutrophils, 
monocytes/macrophages), myeloid dendritic cells, and Natural Killer (NK) cells - but can also be 
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found on CD27+ memory B cells (Ross and Vĕtvicka 1993; Kawai et al. 2005). Its cell surface 
expression is not maintained at a consistent level, but instead is up-regulated from the messenger 
(m)RNA level in response to inflammatory signals. Leukocytes yet to undergo activating stimuli have 
low densities of cell surface receptors that are involved in inflammatory processes, such as CR3 (Ley 
2002). Large intracellular pools of such receptors are stored in secretory vesicles and are available 
for immediate up-regulation of cell surface expression following appropriate activating signals. 
When a neutrophil undergoes this so-called ‘priming’ process, the intracellular vesicles fuse with the 
plasma membrane, releasing the store of receptors, and rapidly increasing their cell-surface density 
(Edwards 1995). Such changes in the expression levels of receptors on leukocytes, in addition to the 
upregulation of their ligands on endothelial cells in response to tissue damage or infection, triggers 
extravasation from the blood, though progression of slow rolling, firm adhesion, and, finally, 
transmigration (Springer 1995).  
 
In addition to the regulation of its cell surface expression, the conformational state of CR3 is also 
modifiable. CR3, and indeed other integrins, undergo conformational changes in response to 
allosteric activation, attributed to the “switchblade” mechanism of activation through receptor 
straightening (Hynes 2002; Kinashi 2006). This mechanism can result from direct interaction of the 
CR3 extracellular domain to a stimulus, resulting in ‘outside-in’ signalling. Additionally, CR3 can 
respond to signals originating from other cell-surface receptors in what is known as ‘inside-out’ 
signalling (Lefort et al. 2009). The same conformational changes occur under both mechanisms, with 
the extension and straightening of the extracellular domain, and separation of the CD11b and CD18 
cytoplasmic tails; ultimately these conformational changes enable high-affinity ligand-binding (Luo, 
Carman, and Springer 2007).  
 
1.4.3 Ligand binding 
 
The ligand-promiscuity of CR3 permits it to carry out many immune functions, and these are 
summarised in Table 1.1 (Ross and Vĕtvicka 1993; Z. Li 1999; van Lookeren Campagne, Wiesmann, 
and Brown 2007; Walzog et al. 1999). The diversity of CR3 ligands ranges from molecules of the 
immune system, including complement factor iC3b and intracellular adhesion molecule (ICAM)-1, to 
pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharides (LPS) from gram-




There are two well-established ligand binding sites on CD11b: the inserted (I)-domain, located near 
the N-terminal headpiece of the polypeptide, and the lectin-like domain, located proximal to the 
transmembrane domain at the C-terminal end of the polypeptide (Diamond et al. 1993; Thornton et 
al. 1996). The I-domain is ~200 amino acids in length and has specificity for ICAM-1, iC3b, and 
fibrinogen (Ross and Vĕtvicka 1993). It is only fully exposed when CR3 occupies an activated state 
following conformation changes. The development of an antibody (clone CBRM1/5) with epitope 
specificity for the I-domain allows CR3 activation to be measured (Diamond and Springer 1993).  
 
Ligation of the lectin-like site, which is constitutively exposed on CR3, induces an intermediate 
‘primed’ conformational state of the integrin receptor (O’Brien et al. 2012). This has been shown to 
enhance I-domain-dependent functions. For instance, the presence of polysaccharides on microbial 
membranes, such as β-glucan on the cell surface of Saccharomyces cerevisiae, recognised by the 
lectin-like site, increases the CR3-dependent cytotoxic activities of neutrophil and NK cell to iC3b-
coated targets  (Xia et al. 1999; Vetvicka, Thornton, and Ross 1996; Vĕtvicka et al. 1999). Likewise, 
the interaction of CR3 with glycosylphosphatidylinositol (GPI)-linked receptors, such as CD16b on the 
cell surface of neutrophils (discussed below in 1.4.4.2), is thought to occur via the lectin-like domain 
and increase CR3 binding to iC3b. 
 
Table 1.1 Summary of CR3 ligands and their origin 
CR3 carries out multiple immune functions due to its specificity for a diverse range of ligands 
Ligand Origin Binding Site Function 
iC3b Opsonised target cells I-domain Phagocytosis; cytotoxixity 
ICAM-1 Endothelial cells I-domain Adherence 
Fibrinogen Extracellular matrix I-domain Adherence 
β-glucan Saccharomyces cerevisiae Lectin-like Receptor priming 
dsRNA Virus ? I-domain Endocytosis 
GPI-linked receptors 
(CD16B, CD14) 
Neutrophils; monocytes Lectin-like Cooperative phagocytosis 
 




1.4.4.1 Intercellular Adhesion 
 
CR3 acts as an intercellular adhesion molecule during leukocyte extravasation. It engages with its 
ligand ICAM-1, which is upregulated on the surface of endothelial cells in response to tumour 
necrosis factor (TNF) and Interleukin (IL)-1 following tissue damage or infection. The paradigm of 
leukocytes extravasation from the blood involves slow rolling, firm adhesion, and transmigration 
(Springer 1995). During weak adhesion and slow rolling, neutrophils may respond to other 
inflammatory signals and, if an activation threshold is reached, β2 integrins switch to the high-
affinity conformational state and result in neutrophil firm adhesion and subsequent transmigration 
(Ley 2002; Ma, Plow, and Geng 2004). The binding of CR3 with ICAM-1 has been shown to regulate 
the velocity of the cells following P-selectin-mediated slow-rolling (Moore et al. 1995; Jessica L 
Dunne et al. 2003), and CD18-, CR3-, or LFA-1 (CD11a/CD18)-deficient mice, were all shown to have 
elevated leukocyte rolling velocities (J. L. Dunne 2002). However, another study using LFA-1-deficient 
mice, together with β2-integrin blocking monoclonal antibodies, suggests CR3 has a minimal role to 
play in firm adhesion and instead mediates the eventual emigration of neutrophils (Henderson et al. 
2001).  
 
1.4.4.2 Phagocytosis  
 
The complement system is a mechanism of opsonising microbes and apoptotic cells for effective 
clearance by phagocytosis. CR3 acts as a phagocytic receptor through its complement factor ligand 
iC3b. This is a product of complement activation, whereby the complement protein C3 is cleaved by 
C3 convertase producing C3a and C3b. Whereas C3a stimulates inflammation by acting as a 
chemoattractant for neutrophils, the larger C3b fragment becomes covalently attached to the 
surface of the target cell where the complement system was activated, acting as an opsonin to 
promote phagocytosis (Abbas, Lichtmann 2012). Indeed ligation of this complement factor to CR3 
alone is sufficient to induce phagocytosis of opsonised targets without the need for synergistic 
activation (Murphy 2012).   
 
CR3 has also been shown to interact with membrane-bound FcγRIIIb (CD16b), which is a GPI-linked 
protein, on the cell surface of neutrophils. CD16b binds IgG but, given the absence of a 
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transmembrane domain, is thought to be unable to transduce cell signals. Strong evidence exists for 
the cooperation of CR3 with CD16b to mediate phagocytosis of IgG-opsonized targets (Krauss et al. 
1994). CR3 is also a receptor for neutrophil-derived soluble (s)CD16 (Galon et al. 1996). Such FcγR-
CR3 interaction is thought to be a reciprocal relationship leading to the activation of CR3 via the 
lectin-like domain located in the C-terminal region of CD11b (discussed above in 1.4.3) thereby 
increasing iC3b binding by CR3 (Stockl et al. 1995). Likewise, on human monocytes, the GPI-linked 
receptor CD14 cooperates with CR3 to phagocytose Borrelia burgdorferi (Hawley et al. 2011). CD14 
is also implicated in the phagocytosis of apoptotic cells, which could further implicate CR3 in 
apoptotic clearance and SLE (Pittoni and Valesini 2002). 
 
1.4.4.3 Immune regulation 
 
CD11b-deficiency has been shown to enhance both Toll-like receptor (TLR)4- (C. Han et al. 2010) and 
TLR9-triggered (Bai et al. 2012) immune responses on murine dendritic cells (DCs). Reports on the 
regulatory role of CR3 following receptor engagement have been somewhat contradictory; 
engagement of monocyte CR3 with anti-CD11b antibodies or soluble CD23 has been shown to 
increase the production of pro-inflammatory cytokines, such as TNF, IL-1β, Macrophage 
inflammatory protein (MIP)-1α, and MIP-1β (Fan and Edgington 1993; Roger Rezzonico et al. 2000; 
R. Rezzonico 2001), and engagement of neutrophil CR3 with an anti-CD18 antibodies has been 
shown to upregulate IL-8 production during the inflammatory response (Walzog et al. 1999); yet 
monocyte CR3 engagement down-regulate the pro-inflammatory cytokine IL-12 and induces IL-10 
secretion (Marth and Kelsall 1997; Yoshida et al. 1998). However, these seemingly paradoxical 
results are explained in light of ligand-avidity; natural ligands induce high-avidity CR3 engagement 
leading to anti-inflammatory responses, whereas low-avidity engagement results in pro-
inflammatory responses (Wang et al. 2010). Furthermore, a recent study demonstrated the 
differential function of CR3 on macrophage and myeloid dendritic cell LPS engagment (Ling et al. 
2014), suggesting cell type, as well as ligand avidity, may also contribute to some paradoxical results 
in the literature. 
 
Very little is known about CR3 function on NK cells, and, despite the growing evidence of CR3 as an 
immune regulator, it is often listed as an activating receptor in the binary categorisation of NK cell 
receptors in review articles (Vivier et al. 2008). NK cells, in particular the CD56bright subset, are 
32 
 
prominent producers of cytokines, therefore CR3 may also play an important regulatory role in the 
cytokine production of NK cells. This is discussed further in section 1.5.  
 
1.5 Natural Killer cells  
1.5.1 NK cells in SLE 
 
Natural Killer (NK) cells are characterised by the presence of CD56 and the absence of CD3, and can 
be divided into two subsets depending on the level of CD56 expression: CD56dim and CD56bright 
(Abbas, Lichtmann 2012). The former, which comprise ~90% of the total NK cells are efficient 
cytotoxic cells and secrete lower levels of cytokines, whereas the CD56bright sub-population secrete 
greater levels of cytokines but only acquire cytotoxicity after prolonged activation (Cooper, Fehniger, 
and Caligiuri 2001; Cooper 2001). NK cells play a regulatory role within the immune system, which is 
of particular interest to inflammatory diseases such as SLE. Following priming by monocyte-derived 
cytokines (monokines) IL-12, IL-15, and IL-18, NK cells secrete pro-inflammatory cytokines, such as 
IFN-γ, which aid the activation of macrophages and dendritic cells (DCs), providing a positive 
feedback loop (Fehniger et al. 1999). Additionally, NK cells have the ability to kill immature DCs, 
hyperactive macrophages, and activated CD4+ T cells through cytotoxicity (Vivier et al. 2008).  
 
Excess IFN-γ production by NK cells has been observed in SLE (Hervier et al. 2011). Historically, 
however, the role of NK cells in SLE has been rather overlooked. However, studies have suggested 
that the NK cells in the peripheral blood of SLE patients are reduced in numbers and function (Park 
et al. 2009; Yabuhara et al. 1996; Schleinitz et al. 2010). A recent study adds further support to these 
findings, with the difference in NK cell number between cases and controls being more pronounced 
in patients with active disease (Henriques et al. 2013).  
 
Genetic studies are also beginning to redirecting our attention towards the involvement of NK cells. 
For instance, as discussed below in section 1.7.4, a consequence of the SLE-associated FCGR3B gene 
deletion also results in the ectopic expression of the inhibitory CD32b on NK cells (Mueller et al. 
2013; van der Heijden et al. 2012). Additionally, polymorphisms in STAT4 – a key mediator of NK cell 
signalling - are among the strongest risk factors for SLE susceptibility (Harley et al. 2008; Bolin et al. 
2013). It has been demonstrated that expression of CD11b and CD27, the TNF-receptor family 
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member, are markers for NK cell maturity, in both mice and humans (Hayakawa and Smyth 2006; 
Silva et al. 2008). However, aside from being a marker of maturity, the role of CR3 on NK cells is 
incompletely understood, and the consequences of the R77H polymorphism on NK cell function have 
yet to be fully explored. In chapter 5 of this thesis I explore the effects of LA1 on the intracellular 
signalling of NK cells, following cytokine activation, as discussed below. 
 
1.5.2 JAK-STAT Signalling 
 
Cytokine signalling through type I and II family cytokine receptors, such as those expressed on NK 
cells, is dependent on the Janus kinase (JAK) and Signal Transducers and Activators of Transcription 
(STAT) pathways. There are four JAKs – JAK1-3 and Tyk-2, and seven STATs – STAT1-4, 5a, 5b, and 6. 
In resting cells, JAKs are non-covalently associated with the cytoplasmic domains of the cytokine 
receptors, and monomeric, non-phosphorylated STAT proteins are present in the cytoplasm. Upon 
ligand-binding, cytokine receptor chains are brought together and associated JAKs are activated, 
which in turn phosphorylate the tyrosine residues in the cytoplasmic receptor domains (Abbas, 
Lichtmann 2012). These phosphotyrosines are recognized by specific STATs; it is this level on which 
cytokine signalling specificity is controlled. Interleukins can activate common JAKs yet their 
downstream signalling can diverge at the STAT level; it is the tyrosine-based motifs in the receptor 
components that dictate their STAT specificity (Stahl et al. 1995; Johnston et al. 1995). For instance, 
IL-12 and IL-13 both utilise Jak-2 and Tyk-2, yet IL-13, unlike IL-12, does not phosphorylate STAT4 
(Yakubenko et al. 2013). Once the Src homology 2 (SH2) domains of the STATs have bound to the 
cytokine receptor chains, they are themselves tyrosine (and serine) phosphorylated by JAKs. 
Phosphorylated STATs can dimerise, enabling their translocation to the nucleus and subsequent 
sequence-specific DNA binding to activate transcription. STATs may form homo- or heterodimers, 
which adds to the level of signalling diversity. Additionally, the roles of STAT5 tetradimers in 






1.7 FCGR locus 
1.7.1 Architecture of the FCGR locus 
 
The FCGR locus on chromosome 1q23.3 encodes five low-affinity IgG receptors; four of which are 
activating - FcγRIIa (CD32a), FcγRIIc (CD32c), FcγRIIIa (CD16a), and FcγRIIIb (CD16b), encoded by 
FCGR2A, FCGR2C, FCGR3A, and FCGR3B, respectively - and FcγRIIb (CD32b) alone, encoded by 




Table 1.2 Expression profiles of the human Fcγ receptors and their association with SLE.  
Receptors are listed in the order of their encoding genes, from centromere to telomere, along 
chromosome 1q23., The number of cases and controls used plus the p-values obtained for 



















F158V (3493/2426, pmeta=0.0001; L.-H. Li et al. 2010) 
FCGR2C CD32c, 
FcγRIIc 
NK cells, B cells n/a 
FCGR3B CD16b, 
FcγRIIIb 
Neutrophils Reduced CN (1808/3565, pmeta=9.1x10




B cells, monocytes, 
macrophages, DCs 
232T-homozygosity (2287/3596, pmeta=8x10






Due to evolutionary segmental duplication, the locus is split into two ~85Kb paralogous blocks that 
share an estimated overall homology of 93.7% (Mueller et al. 2013). The centromeric block contains 
FCGR2A, FCGR3A and the 5’ end of FCGR2C; the telomeric block includes the 3’ end of FCGR2C, 
FCGR3B and FCGR2B (Figure 1.1). As with other regions displaying CNV, this segment homology is 
thought to account for the CNV seen at both FCGR3A and FCGR3B (Mueller et al. 2013). There is a 
higher frequency and broader range of CNV at the FCGR3B gene compared with FCGR3A (Breunis et 
al. 2009). FCGR2C arose from the same segmental duplication: its 5’ end is 99.2% homologous to 
that of FCGR2B, and its 3’ end is homologous to that of FCGR2A (Figure 1.1A). It is often thought of a 
pseudo-gene as only ~18% of Europeans possess a variant in exon 3 of FCGR2C which alters the stop 
codon to an open reading frame (ORF). In the presence of this ORF, CD32c is expressed on B cells 
and NK cells (Metes et al. 1998; Xinrui Li et al. 2013). 
 
This locus has long been known for its influence on autoimmunity. There are multiple SLE 
associations with polymorphisms spanning the locus, including FCGR2A-R131H (rs1801274), FCGR3A-
F158V (rs396991), FCGR3B copy number variation (CNV), and FCGR2B-I232T (rs1050501), as 
summarised in Table 1.2, implicating under-functioning of these receptors in IC clearance and 
















Figure 1.1 The FCGR locus on chromosome 1q23.3  
A) shows the genomic composition of the five FCGR2/3 genes in the absence of a gene deletion. Red 
and blue shaded boxes represent the region involved in the 85Kb segmental duplication, with the 
darker shades highlighting the 24.5Kb containing the breakpoint. B) shows the genomic composition 
in the presence of an 85Kb deletion, resulting in complete absence of FCGR3B and the amalgamation 
of FCGR2C/FCGR2B forming the chimeric FCGR2B’ gene. The purple segment is representative of the 










1.7.2 Reduced copy number of FCGR3B 
 
Evidence of a contribution to SLE risk from the copy number variation within this locus came from 
the rat Fcgr3 and human orthologous FCGR3B genes, whereby a reduced copy number (<2) was 
found to be associated with glomerulonephritis (Aitman et al. 2006). Using a quantitative (q)PCR 
assay, low copy number of FCGR3B was later confirmed to be associated with systemic 
autoimmunity in two independent cohorts of European ancestry (Fanciulli et al. 2007). However, the 
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accuracy of using qPCR to measure CNV has since been questioned. A novel PCR-based assay called 
the Paralogue Ratio Test (PRT; described in section 2.11) was developed for high-throughput copy 
number calling (Armour et al. 2007), and the technology has been successfully employed for the 
study of CNV at multiple loci across the human genome, aiding the understanding of this structural 
variation in human disease (Walker, Janyakhantikul, and Armour 2009). Applying the PRT to the 
FCGR3 locus allowed more accurate copy number calling, and replicated the association with SLE in 
European (P=0.018; OR=1.57) and Chinese (P=4 x 10-4; P=1.65) cohorts (Niederer et al. 2010b). Meta-
analyses have confirmed this robust association between reduced copy number of FCGR3B and SLE 
(Pmeta=9.1x10
-7, OR=1.59; McKinney & Merriman, 2012). FCGR3B CNV has since been shown to be 
correlated with both CD16b protein expression on neutrophils and soluble serum levels of CD16b. 
Furthermore, the reduced expression was shown to impair immune complex binding and clearance 
by neutrophils, thus adding a functional perspective to the genetic association (Willcocks et al. 
2008).  
 
The NA1 and NA2 allotypes of CD16b differ by five amino acids and are encoded by two alleles which 
differ by six single nucleotide variations, one of which encodes a synonymous codon, within FCGR3B. 
NA1 has been shown to be the allotype with the highest affinity for IgG (Salmon, Edberg, and 
Kimberly 1990). The association within FCGR3B was further extended to a biallelic-CNV model, 
whereby disease risk associated with gene deletion being greater for the higher-affinity NA1 allotype 
than the lower-affinity NA2 (Morris et al. 2010). Despite conflicting results regarding the LD between 
FCGR3B copy number and surrounding FCGR SNPs in the studies by Morris et al. and Niederer et al., 
both studies concluded that reduced copy number of FCGR3B was an independent risk factor for SLE 
(Morris et al. 2010; Niederer et al. 2010b). 
 
1.7.3 FCGR2B-I232T and SLE 
 
The rs1050501 non-synonymous polymorphism (Chr1:161643798), located in exon 5 of FCGR2B 
gene, was initially identified in a Japanese cohort. The SNP encodes an isoleucine (I) to threonine (T) 
amino acid change at codon 232 of the CD32b polypeptide - the only inhibitory receptor in the FcγR 
family – and 232T-homozygosity was found to be associated with SLE (Kyogoku et al. 2002). This 
association has since been replicated in other East Asian populations (Chen et al. 2006; Chu et al. 
2004; Siriboonrit et al. 2003).  
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There have been some inconsistencies regarding the association of FCGR2B-I232T with SLE in 
European cohorts, with some studies reporting no association (V. Magnusson 2004; Xiaoli Li et al. 
2003). However, these studies had relatively small sample sizes, particularly given the low MAF (0.1) 
in Europeans (Clatworthy et al. 2007), compared with that in East Asians (0.22-0.25) (Chen et al. 
2006; Chu et al. 2004; Siriboonrit et al. 2003). However, a larger case-control study using UK cohorts 
found a significant association (p=0.014; OR=2.8) between 232T-homozygosity and SLE (Willcocks et 
al. 2010). Furthermore, a meta-analysis of the published European studies showed an OR of 2.06 
(p=0.022) for 232T-homozygosity, providing strong evidence of association (Willcocks et al. 2010).  
 
Amino acid 232 forms part of the transmembrane domain of CD32b and the I232T variant has been 
show to affect the formation of lipid rafts, thus reducing the regulatory function of CD32b on B cells 
and macrophages (Floto et al. 2005; Kono et al. 2005). Interestingly, the minor allele of the I232T 
variant has also been shown to be protective against progress to severe malaria following infection, 
as the under-functioning minor allele enhanced phagocytosis of infected erythrocytes through a 
mechanism of reduced inhibition (Willcocks et al. 2010; Clatworthy et al. 2007). The relatively high 
frequency of the minor alleles of some complex disease-associated polymorphisms does suggest 
positive selection pressure under particular environmental conditions, and given that severe malaria 
infection is strongly associated with childhood mortality, the I232T variant could be an example of 
such a phenomenon (Clatworthy et al. 2007). SLE has a higher prevalence, and is more severe, in 
South-East Asian and African populations, which are areas historically troubled by malaria infections 
(Clatworthy et al. 2007). This is reflected in the increased MAF of some associated variants in these 
populations, compared with European population (Willcocks et al. 2010).  
 
1.7.4 Ectopic Expression of CD32b 
 
Recently the effect of the FCGR3B gene deletion has been explored in the broader context of the 
locus. The ~85Kb deletion extends across the entire FCGR3B gene, upstream into the 5’ end of 
FCGR2C and downstream into the 5’ end of FCGR2B. The breakpoint has been mapped to within a 
24.5Kb region of complete sequence homology in the 5’ region of FCGR2C and FCGR2B (Figure 1.1). 
The absence of sequence duplication surrounding the deletion suggests the breakpoint creates a 
seamless amalgamation of the FCGR2C and FCGR2B genes (Mueller, 2013). Furthermore, this 
chimeric FCGR2C/FCGR2B gene, termed FCGR2B’, has the 3’ coding region deriving from FCGR2B yet  
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is under the regulatory control of that of FCGR2C, which results in the ectopic expression of the 
inhibitory CD32b receptor on NK cells (van der Heijden et al. 2012; Mueller et al. 2013). The 
functionality of CD32b on NK cells has yet to be demonstrated. However, effector functions of NK 
cells are controlled by the fine balance of many activating and inhibitory receptors, therefore the 
ectopic expression of this uniquely inhibitory Fc receptor is very intriguing. In Chapter 6 of this 
thesis, I explore the possibility of a genetic interaction between FCGR3B CNV and the FCGR2B-I232T 
polymorphisms. It is possible that part of the genetic association seen with reduced CNV is due to 
the ectopic expression of CD32b; it is also possible that the effect size of the FCGR2B-I232T 
association is underestimated without the consideration of FCGR3B CNV. That is, the under-
functioning CD32b-232T variant may also contribute to SLE risk when ectopically expressed on NK 
cells, as has been demonstrated with B cells and macrophages (Kono et al. 2005; Clatworthy et al. 
2007).  
 
1.8 Summary and project aims 
 
The ‘waste disposal’ hypothesis is a central paradigm of SLE disease biology, and refers to the under-
functioning of apoptotic clearance by phagocytes. In support of this notion, genetic variants in genes 
encoding phagocytic receptors, such as ITGAM and the FCGR genes, are among the strongest risk 
factors contributing to SLE susceptibility. The study of the genetic variations associated with disease 
risk will ultimately aid our understanding of the immunological mechanisms contributing to disease 
onset, as they are not affected by disease progression, and will hopefully aid the development of 
targeted therapeutics. 
 
The work presented in this thesis aims to: 
 
 Determine the impact of the ITGAM common polymorphism rs1143679 (CD11b-R77H) on 
cell surface expression of CR3 
 Investigate the contribution of rare variants within ITGAM to SLE 
 Explore the underlying NK cell signalling effects of a potential CR3-targetted therapeutic 
 Test for the potential genetic interaction between two SLE-associated variants within the 
FCGR locus – FCGR3B CNV and FCGR2B-I232T 
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Chapter 2: Methods 
 
2.1 Samples 
2.1.1 Ex vivo cells 
 
Whole blood was obtained with consent from healthy volunteers, with no history of autoimmunity, 
from the Twins UK National Institute for Health Research (NIHR) Bioresource. Heparin was used an 
anti-coagulant and samples were processed on the same day as blood collection.  
 
2.1.2 DNA 
2.1.2.1 UK SLE cohort 
 
The genomic DNA from SLE patients of European ancestry used in the following studies were 
collected by Professor Tim Vyse (ethical approval MREC/98/2/6 and 06/MRE02/9) prior to the start 
of this project. Each proband met the American College of Rheumatology (ACR) 1982 revised criteria 
for diagnosis (Tan et al. 1982). 
 
2.1.2.2 Control Cohorts 
 
Genomic DNA from healthy controls of European ancestry from the Wellcome Trust Case Control 
Consortium (WTCCC) 1958 birth cohort and TwinsUK National Institute for Health Research (NIHR) 
Bioresource were used as stated below.  
 
 
2.2 Cell surface expression of CD11b on ex vivo cells by flow cytometry 
 
Whole blood was used to measure cell surface expression of CD11b, and percentage of activated 
CD11b, on neutrophils and monocytes, under both resting and activated conditions, by 
Fluorescence-Activated Cell Sorting (FACS). Healthy volunteers (2.1.1) were used in pairs of opposing 
homozygous genotypes for the SLE-associated polymorphism rs1143679: R77-homozygous (WT) and 
77H-homozygous. 20ml whole blood was enriched for leukocytes by sedimentation in 3% dextran-
500, which removes erythrocytes. Samples were resuspended in Hank’s balanced salt solution 
(HBSS) with 20 mM HEPES, 1 mM calcium chloride and 1 mM magnesium chloride. Cell activation 
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was achieved by incubation with 200nM phorbol myristate acetate (PMA, Sigma) for 10 minutes at 
37°C.  
 
Four leukocyte-enriched whole blood aliquots of 2.5 x105 cells were stained for 45minutes at 4°C 
with PerCyP-conjugated anti-CD14 and one of the following monoclonal antibodies:  
 
1. PE-conjugated anti-CD11b (clone: ICRF44)  
2. PE-conjugated IC 
3. APC-conjugated anti-CD11b (clone: CMBR1/5)  
4. APC-conjugated IC 
 
 
Following cell surface staining, red blood cells were lysed using Lysis Sloution© (BD Bioscience) and 
cells were fixed using BD FACS Fixative Solution© (BD Bioscience). Samples were run on a BD FACS 
CANTO II flow cytometer using BD FACS Diva software. 30,000 events were collected. Forward-
scatter (FSC) and side-scatter (SSC) area were used to identify the neutrophil population based on 
their cell size and granularity, respectively. The anti-CD14-PerCyP mAb was used to identify the 
CD14+ monocytes. The anti-CD11b (clone: ICRF44) antibody and PE conjugated isotype control were 
used to measure total cell surface expression of CD11b. The anti-CD11b (clone: CMBR1/5), which 
recognizes an epitope on activated CD11b molecules (Diamond and Springer 1993), and APC-
conjugated isotype control were used to measure the percentage of activated CD11b. FlowJo 
Software (version 7.6.4) was used to analyse the FACS data, and GraphPad Prism v.5 was used to 
compare mean fluorescent intensities (MFI) between genotype groups with a paired t-test. 
 
 
2.3 Amplification of 500bp upstream of ITGAM start codon 
 
I Polymerase Chain Reaction (PCR) amplified 40ng of genomic DNA by with 0.5U Hot Star Taq 
polymerase (Qiagen) and 0.5μM of each of forward (5’-CACCATGCCCAGCTAATTAAA) and reverse (5’-
CTCCTCCCCACCCAGAGT) primers (Sigma Aldrich) in a total volume of 10μl (See Appendix A1 for full 
details). The primers were designed using Primer3 (v.0.4.0) software (http://frodo.wi.mit.edu/) and 
gave a product size of 587bp. The reverse primer is located in exon 1 to ensure I could sequence 
upstream of the start codon. Amplification was carried out on a G-Storm T4 thermocycler (see 
Appendix B1 for thermocycler conditions). 
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2.4 Capillary Sequencing  
 
2.4.1 PCR confirmation and EXO-SAP clean-up 
 
I ran 7µl of PCR product on a 2% agarose gel with 0.00025% (v/v) ethdium bromide, and observed 
the stained gels with a UV-transilluminator. I cleaned 1µl of the PCR products by adding 5.75µl ddH20 
and 0.25µl EXO-SAP (VWR), and incubating the samples at 37°C for 30 minutes, followed by an 
enzyme-inactivating step at 80°C for 15 minutes, to remove excess primers and dNTPs.  
 
 
2.4.2 Big Dye© reaction 
 
3.5μl of the EXO-SAP product (clean, amplified DNA) was labelled with 0.25μl Big Dye© v3.1 (Life 
Technologies), with 5 pmoles primer (same as used for PCR, unless otherwise stated), in a total 
volume of 5.25μl. The samples were incubated at 96°C for 30 seconds, 50°C for 15 seconds, and 60°C 
for 60 seconds, for a total of 30 cycles in a G-Storm T4 thermocycler. 
 
I added 5.25µl of an ethanol-based precipitation solution (Appendix C1) to clean the DNA product 
following the Big Dye© reaction. This was incubated at room temperature for 15 minutes followed 
by a 30 minutes centrifugation at 3000rpm. The solution was removed from the pelleted DNA with a 
short 10 second centrifugation of the inverted plate at 400rpm. I added 100µl of 70% ethanol, to 
clean the DNA, and centrifuged for 10 minutes at 3000rpm. Once more, a short centrifugation at 
400rpm was used to remove the ethanol and the DNA pellet was further dried for 5 minutes at 60°C 
on a thermocycler. I added 10µl of Hi-Di formamide (Applied Biosystems) to each well of the 96-well 
plate and the DNA was then denatured at 95°C for 2 minute. 
 
 
2.4.3 ABI 3730xl DNA Analyser and Analysis 
 
The samples were processed on an ABI 3730xl DNA analyser (Applied Biosystems) in the King’s 





2.5 Discovery of rare coding variants within ITGAM  
2.5.1 454 sequencing and analysis 
 
This work was performed by Ellen Thomas and Shriram Bhosle, Imperial College London. 
 
Genomic DNA from 73 SLE patients meeting American College of Rheumatology criteria underwent 
whole genome amplification (Qiagen Repli-G). Ethical approval was given by London Multicentre 
Research Ethics Committee and participants gave written consent. Standard (KOD polymerase, 
Merck) and long-range (Sequalprep, Invitrogen) PCR reactions were carried out in 13 amplicons, 
giving products between 600 base pairs and 4 kb in length, covering 24 kb of the ITGAM gene 
including all thirty exons. The PCR products were run on an agarose gel and purified using the Qiagen 
MinElute 96 UF PCR Purification Kit. Seven amplicons greater than 1.5kb were pooled and sheared to 
fragments of 500-800bp on the Covaris E210.  The six short PCR products were added to the sheared 
products and each pool was tagged with a unique DNA barcode using the Parallel Tagged Sequencing 
(PTS) protocol (Meyer, Stenzel, and Hofreiter 2008), starting at the blunt end repair step. The 
barcoded PCR products were quantified using the Invitrogen Quant-iT Picogreen dsDNA kit and 
combined into a single pool using 10ng of each tagged sample. Dephosphorylation and restriction 
digestion was carried out according to the PTS protocol and the pool of sheared and indexed PCR 
products was taken through 454 Titanium library preparation according to the manufacturer’s 
protocol (GS FLX Titanium General Library Preparation Method Manual v5.3.2), starting at step 3.5. 
Library quality was checked using an RNA Pico 6000 assay on the Agilent Bioanalyser and quantified 
using a RiboGreen assay (Thermo Fisher Scientific) using the Nanodrop 3300 fluorospectrometer. 
The library was diluted to 1 x 108 molecules/µl, amplified and sequenced according to the 
manufacturer’s protocol for 454 GS FLX sequencing. With 896,206 reads which passed filters, an 
average coverage of 105x was achieved. 88% of the samples were covered at a level sufficient for 
variant calling (more than 10 reads) in at least 80% of the target region. Additional PCRs (KOD 
polymerase, Merck) were generated covering exons 8, 13 and 14 due to low coverage in the 454 
data. Capillary sequencing of these amplicons used the 3730xl platform (Applied Biosystems). 
 
454 sequence read demultiplexing used ‘untag’ software (Meyer, Stenzel, and Hofreiter 2008), base 
calling used Pyrobayes (Quinlan, Stewart, and Marth 2008), and alignment to the reference genome 
used BWA  (H. Li and Durbin 2009). Variant calling was carried out using GATK (McKenna et al. 2010) 
without duplicate read removal, using hard filters: coverage at least 10-fold, genotype quality 
threshold 50, SNP quality threshold 30, and allele balance threshold 0.75. 
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2.5.2 Confirmation of rare variants by capillary sequencing 
 
Table 2.1 summarises the 17 potential novel variants observed in the 454 sequencing of ITGAM; 16 
of which are non-synonymous coding variants (named conventionally by the codon number and 
change in amino acid), and one splice site variant. Primer pairs (Sigma Aldrich) were designed using 
the Primer3 (v.0.4.0) software (http://frodo.wi.mit.edu/) to produce amplicons <400bp of ITGAM 
regions containing the putative variants. The small sizes of the amplicons enabled easy amplification 
and sequencing.  
 
I amplified 30ng of genomic DNA from the appropriate SLE samples in a total volume of 20µl 
(reaction conditions are summarised in Appendix A). Amplification was carried out on a G-Storm T4 
thermocycler, as summarised in Appendix B. Capillary Sequencing was carried out as above 
























Table 2.1 Summary of primers used for PCR amplification of ITGAM regions containing putative 
rare variants 
Variants are named in the conventional format: amino acid change and the codon numbers. A stop 
codon is designated by *. Splice variant is named by the genomic location and ‘SS’ prefix. Purple 
shading indicates the novel variants confirmed by capillary sequencing. 
 
Forward Primer Reverse Primer Tm(°C) CD11b Variant 
5' CTCCCCACATGTCGAAGTTT 5' ACACAGGAGTGCCTGGAAAG 56.8 Q79* 
5' TTGTCCCTCCTGTTTCCTGC 5' CTGTCTGCCTCAGGGATGAC 56.8 R246Q 
5' TTGCTAGCCTCACACCATGA 5' CAGATGCCTGACTCACCCTC 53 K295E 
5' TGCCTTCCGCAGTGAGAAAT 5' CAGATGCCTGACTCACCCTC 56.8 
A320T 
N326D 
5' CCCCCATTACTACGAGCAGA 5' AAACAGTATCAGGCCCCAAC 56.8 R498G 
5' CACAGCTGAGAAGCAGAGGA 5' GGGTCCTCGATGCAATTCTA 56.8 
S672G 
L680Q 
5' CACAGCTGAGAAGCAGAGGA 5' GACCCCAACTCTGGACTCAC 53 F735S 
5' GTCTCTGTTCTGCTGGAGCA 5'ACAGGTCAAGCGGGAAGAAG 56.8 L792P 
5' TGTCTGCGTCTCTGTTCTGC 5' TTCCGGTAGGACAGGTCAAG 56.8 SS31336581 
5' ACCCATTACCCATGTGCCTG 5' ATCGATTTTCCTCCCCAGCC 56.8 F941V 
5' AACCCCCAGAAATCCAGAGT 5'AGAGACTGAGGCGCAGAGAG 56.8 
V1019L 
V1019A 
5' ACATCAAGGTGTGTGGGGTC 5' ATAGTTCCTCAGCGCCCAAG 56.8 S1068R 










2.6 Genotyping novel rare variant in larger cohorts  
 
2.6.1 Site-specific primer (SSP) PCR  
2.6.1.1 Theory 
 
The site-specific primer polymerase chain reaction (SSP-PCR) is a multiplex PCR with four primers; a 
pair of non-allele-specific ‘outer’ primers, and a pair of allele-specific ‘inner’ primers (Figure 2.1). It is 
essential that the final 3’ nucleotide of a primer aligns perfectly with the DNA template for 5’-3’ DNA 
extension within a PCR reaction. It is therefore possible to utilise this for allele-specific amplification. 
The final 3’ nucleotide of the two inner primers – forward and reverse - of an SSP are designed to 
overlap at the polymorphic nucleotide of interest, and each primer is specific for one allele. 
Therefore, each inner primer will only be capable of mediating DNA extension from one of two 
possible alleles.  
 
There are three possible PCR products from the various combinations of ‘outer’ and ‘inner’ primers, 
and if designed to yield amplicons of various sizes, they can be easily visualised under UV light 
following ethidium bromide gel electrophoresis to give high-throughput genotyping (Figure 2.1).  
 
2.6.1.2 Genotyping F941V by SSP-PCR 
 
Using the Primer3 (v.0.4.0) software (http://frodo.wi.mit.edu/), I designed four primers to give three 
possible PCR amplicons as summarised in Table 2.2 and 2.3. 
 
The DNA from 345 SLE cases was genotyped using 96-well plates including a positive heterozygous 
control (88:2.1) and a ddH2O negative control on each. Amplification of 10ng of genomic DNA was 
carried out in a total volume of 10µl, and the reaction and thermocycler conditions are summarised 
in Appendix 1. Following amplification on a G-storm T4 thermocycler, 7µl of PCR product was run on 
a 2% agarose gel with 0.0025% (v/v) ethidium bromide and visualised with a UV-transilluminator. 






Figure 2.1 Schematic representations of the F941V SSP-PCR primer combinations and the resulting 
gel electrophoresis banding pattern 
Arrows of matched colours signify paired forward and reverse primers and their resultant amplicon 
sizes. The final 3’ nucleotides of the inner primers have allele-specificity for the polymorphism of 
interest (shown in bold). Lanes 1 and 2 show samples homozygous for the wild-type ‘T’ allele. Lanes 
3 and 4 show samples heterozygous for the rare variant; both ‘T’ (265bp) and ‘G’ (151bp) alleles 
have been amplified. All four DNA samples contain the non-allele-specific 372bp control amplicon. 















Table 2.2 SSP-PCR primer sequences and specificities 
Allele-specific nucleotides at the 3’ end of the inner primers are indicated in bold 
Primer Name Primer Sequence 
Allele 
specificity 
Amino Acid Specificity 
Outer Forward 5’ TTGTGACGTGTGTGTGAGT - - 
Outer Reverse 5’ CCATCCCTGTTTCTGCATTT - - 
Inner Forward 5’GGGTCTCCACTAAATATCTCAACG G Valine 
Inner Reverse 5’ GGTATTCTCTGAGGCCGTGAA T Phenylalanine 
 
 
Table 2.3 SSP-Primer possible combinations 
The three possible PCR amplicons produced by the forward and reverse primer combinations 
Forward Primer Reverse Primer Allele-Specificity Amplicon size (bp) 
Outer Forward Outer Reverse - 372 
Outer Forward Inner Reverse T 265 




2.6.2 Genotyping F941V and G1145S on the Illumina Custom 384 Chip 
 
An Illumina Custom 384 Chip was designed to genotype 384 SNPs in 1,772 SLE samples of European 
ancestry (2.1.2) to validate the findings of the recent SLE GWAS conducted in the laboratory of Prof. 
Tim Vyse. Both F941V and G1145S rare variants were included on this chip in order to estimate the 
frequency of both novel rare variants in a large SLE cohort. This work was carried out at UPPSALA, 
Sweden. Heterozygous samples 88:2.1 and 50:2.2 were included in the samples as positive controls 
for genotype calling. I provided the surrounding sequences (150b upstream and downstream), and 
nucleotide changes, to Thomas Axelsson (UPPSALA, Sweden) and James Bentham (King’s College 





2.6.3 Genotyping G1145S by capillary sequencing 
 
The G1145S variant failed Quality Control for genotype calling for the Illumina Custom 384 Chip 
(2.6.2), possibly due to its proximity (3bp) to the P1146S common polymorphism. For the same 
reason, I was not confident that an SSP-PCR assay for G1145S would be robust. Therefore I used 
capillary sequencing and Big Dye technology, as described above in section 2.4, to genotype G1145S 
in 949 additional SLE cases. I used the same primers, PCR reaction composition, and thermocycler 
conditions for G1145S amplification as previously described in section 2.5.2. Samples were amplified 
in 96-well plates, with each plate containing a positive heterozygous control (50:2.2) and a ddH2O 
negative control. 
 
2.6.4 Rare variants in online datasets 
 
I utilised a large-scale publicly-available sequencing project dataset to screen ITGAM for the 
confirmed rare variants in healthy controls of European ancestry. The National Heart Lung and Blood 
Institute’s (NHLBI) Exome Variant Server (http://evs.gs.washington.edu/EVS/) documents exome 
sequencing of 8600 European-American chromosomes. 
 
2.7 In silico analyses of F941V and G1145S  
2.7.1 Comparisons of human CD11 amino acid sequences 
 
 
I used the MultAlin software (Corpet, Cellulaire, Toulouse, & Tolosan, 1988; 
http://multalin.toulouse.inra.fr/multalin/) to compare the protein sequences of the four human 
CD11 molecules that pair with CD18 as part of the β2 integrin family. The four proteins CD11a, 
CD11b, CD11c and CD11d are encoded by ITGAX, ITGAM, ITGAL, and ITGAD, respectively.   
 
2.7.2 Functional Prediction tools 
 
I used two online algorithms, PolyPhen (Adzhubei et al. 2010) and SIFT (Kumar, Henikoff, and Ng 





2.8 In vitro studies of function  
2.8.1 Site-directed mutagenesis 
 
10ng of a pcDNA3.1-CD11b vector (Life Technologies) was mutated to contain one of four ITGAM 
variants – F941V, G1145S, M441T, and A858V - using the PCR-based QuikChange II XL Site-Directed 
Mutagenesis kit (Agilent). The primer sequences and PCR reaction composition is summarised in 
Apppendix A, and the thermocycler conditions are summarised in Appendix B. Following the 
mutagenesis, 1µl DpnI enzyme was added directly to the 50µl PCR reaction and incubated at 37°C for 
one hour to digest the parental plasmid DNA. 
 
2.8.2 Bacterial transformation and colony selection 
 
45µl of XL-10 Gold Ultra-competent cells were incubated with 2µl of β-mercaptoethanol and 2µl 
Dpn-I digested plasmid DNA on ice for 30 minutes followed by 30 seconds at 42°C in a water bath, 
and a further 2 minutes on ice. 0.5ml pre-warmed S.O.C. medium was added to the transformed XL-
10 Gold Ultra-competent cells and placed in a shaking incubator for one hour at 37°C. 
Agar plates containing 0.1mg/ml carbenicillin were coated with 200µl of the bacterial culture and 
incubated over-night at 37°C. Ten colonies per variant were then individually picked and placed into 
5ml LB Broth (plus 0.1mg/ml carbenicilin) in 50ml falcon tubes, and inoculated at 37°C in a shaking 
incubator over-night. 
 
2.8.3 Mutation screening 
 
A Qiagen mini-prep kit, as per the manufacturer’s instructions, was used to isolate a small amount of 
DNA from the over-night inoculations. I used capillary sequencing, as described in section 2.4.2 
above, to sequence the plasmids in forward orientation for mutation screening. Table 2.4 lists the 
primers used. These primers were designed using the ITGAM cDNA sequence and Primer3 (v.0.4.0) 
software (http://frodo.wi.mit.edu/) and purchased from Sigma Aldrich. Glycerol stocks were also 
made for each of the cultures and stored at -80°C. Once the mutagenesis was confirmed to be 
successful, the corresponding glycerol stocks were thawed slightly and plated by dilution method on 
agar plates (plus carbenecillin) and incubated at 37°C overnight to produce single colonies. A single 
colony was picked and inoculated in 100ml LB Broth for 12-16 hours at 37°C for use with a Maxi-prep 
kit (Qiagen), as per the manufacturer’s instructions. 
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Table 2.4 Primers used for mutation screening by capillary sequencing 
 







2.8.4 Maintenance of COS-7 cells 
 
The simian fibroblast cell line, COS-7 (ATCC), were maintained in Dulbecco's Modified Eagle Medium 
(DMEM; Life Technologies), supplemented with 10% foetal bovine serum (FBS) and 1% 
Penicilin/Streptomycin, in a cell culture incubator at 37°C and 5% CO2. These adherent cells were 
typically grown in T75 flasks (Nunco) in a total volume of 10ml. Media were removed from flasks 
with an aspirator and the cells were washed twice with 10ml phosphate buffered solution (PBS) to 
remove any residual serum. 1ml of trypsin solution (Sigma) was then added to the cell layer and 
incubated for ~3 minutes at 37°C to loosen the cells from the flask. 
 
2.8.5 Transient Transfections  
 
Following trypsinisation, I estimated the number of COS-7 with Trypan Blue and a Countess™ 
(Invitrogen) automated cell counter and then pelleted 1x106 cells at 300g for 10 minutes per 
transfection.  The cells were resuspended in 100µl Nucleofector Solution R (Lonza). To co-transfect 
the cells, I added 1.25 g of one of five pcDNA3.1-CD11b vectors (WT, M441T, A858V, F841V or 
G1145S) together with 1.25  g pcDNA3.1-CD18 and used COS-7 (ATCC) programme on a 
Nucleofector II (Lonza) machine. In duplicate, 40 x 104 cells were added to an acid-cleaned coverslip 
in a 24-well plate. The remaining transfected cells were cultured overnight in a T25 flask for 
expression screening by flow cytometry. 
 
2.8.6 Measuring CR3 expression on transfected COS-7 cells  
 
One day after transfection, cell-surface expression of CR3 was measured using a PE-conjugated anti-
CD11b (clone ICRF44; eBioscience). Transfected cells were stained in the dark for 30mins on ice and 
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processed on a BD FACS Canto II flow cytometer. Live COS-7 cells were identified by plotting FSC-
area against SSC-area using FACS DIVA software (BD Bioscience). 10,000 events were collected 
within this gate.  
 
I used FlowJo software v.7.6.4 to estimate the percentage of CR3 positive cells and the mean 
fluorescence intensity (MFI) of the positive population. I compared expression levels of CR3 in the 
WT, M441T, A858V, F941V and G1145S transfected cells by using the MFI values and a paired two-
tailed t-test on Prism5 software (GraphPad). 
 
2.8.7 Phagocytic Assay 
 
This was carried out on the same day as the flow cytometry expression analysis. 5µl (=2.5x106) sheep 
red blood cells (sRBCs) in Alsevier (TCS Biosciences) were incubated with 10µl goat anti-sheep IgG 
(Sigma) in 500µl Gelatin veronal buffer (GVB; Sigma) and rotated on a daisy wheel at room 
temperature for one hour. Following this, the IgG opsonized red cells were pelleted 4000rpm for one 
minute and resuspended in 90µl GVB plus 10µl C5-depleted human serum (Sigma), and incubated at 
37°C for 20 minutes in a water bath. The iC3b-opsonized sRBC (sRBCiC3b) were pelleted at 4000rpm 
for one minute and resuspended in 500µl serum-free DMEM. I then further diluted the sRBCiC3b 1:50 
in serum-free DMEM, to obtain a final concentration of 1x105cells/ml. 
 
 
Transfected COS-7 cells were incubated with 500µl (=50,000 cells) of the sRBCiC3b mixture for 30 
minutes at 37°C, 5% CO2 in a tissue culture incubator. In order to stop phagocytosis, the 24-well 
plate was placed on ice before the sRBCiC3b–containing DMEM was removed. Externally bound 
sRBCiC3b were stained with 200µl of a 1:300 dilution in 5% Bovine Serum Albumin (BSA)/PBS of an 
Alexa-488 conjugated mouse anti-goat IgG antibody (Invitrogen) in the dark and on ice for 8 
minutes. Following this, the cells were fixed with 200µl 4% paraformaldehyde (PFA; VWR) for 10 
minutes at room temperature and then permeabilised with 200µl of 0.2% Triton-X (Sigma) for 3 
minutes. The cells were washed twice with 0.5ml 0.5% BSA/PBS before the internal and external 
sRBCiC3b were stained with 200µl of a 1:300 dilution (in 5% BSA/PBS) of an Alexa-555 conjugated 
mouse anti-goat IgG antibody (Invitrogen), and the COS-7 nuclei were stained with 0.5μl DAPI, 
protected from light at room temperature for 40 minutes. The cells were washed with 0.5% 
BSA/PBS, followed by PBS, and finally 1ml ddH2O, before being removed from the 24-well plate with 
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fine-pointed curved forceps and mounted individually onto 4µl Mowiol (Calbiochem) on microscope 
coverslips (VWR). They were left to dry overnight, protected from the light. 
 
2.8.8 Fluorescent Microscopy 
 
I used a Zeiss Axiophot fluorescent microscope, with x20 lens, and attached camera to photograph 
the coverslips for further analysis. A UV-light, green fluorescent, and blue fluorescent filter was used 
to excite the DAPI-stained nuclei, the Alexa-555 labeled sRBCiC3b (external and internal of the COS-7 
cells), and Alexa-488 labeled sRBCiC3b (external), respectively, and three JPEG images were created 




I visually analysed the photographs using Microsoft Picture Viewer. For each COS-7 cell, I counted 
the Alexa-555 labeled sRBCiC3b, which represent all associated sRBCiC3b (internal and external), and 
calculated the Association Index (AI) using the following equation: 
 
                  
                       sRBCiC3b
               
 
 
Because the Alexa-488 is used to stain sRBCiC3b before COS-7 cell permeabalisation, only sRBCiC3b 
engaged with CR3 on the outside of the COS-7 cell are labeled. Therefore, in this assay, a phagocytic 
event is represented by a sRBCiC3b which is labelled with Alexa-555 but has no equivalent Alexa-488 
stain. By counting the number of sRBCiC3b stained only by Alexa-555, I calculated the Phagocytic 
Index (PI) and Percentage Phagocytosis (PP) using the following equations: 
 
                  
                            sRBCiC3b
               
 
 
                         
                            




I used two-tailed paired t-tests to compare the AI, PI and PP between CD11b-WT and each of the 
four variants on Prism5 software (GraphPad). 
 
2.9 Effects of LA1 on NK cell viability and signalling 
2.9.1 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from 50ml of whole blood from healthy 
volunteers (2.1.1), plus 100µl heparin, by density gradient separation. Whole blood diluted 1:3 with 
phosphate balanced solution (Invitrogen) was layered onto 15ml of Histopaque (Sigma) in 50ml 
falcon tubes (Becton Dickson) and centrifuged for 20 minutes at 800g with no brake. The PBMC rings 
were removed and washed twice – once with PBS and once with 1%BSA/PBS - to remove any 
contaminating platelets. The number of live cells was calculated using Trypan Blue and a Countess™ 
(Invitrogen) automated cell counter. 
 
2.9.2 Isolation of NK Cells 
 
I used a MACS NK cell negative isolation kit (Miltenyi Biotech) to separate untouched NK cells from 
other mononuclear cells. This is achieved by firstly incubating the PBMCs with a Biotin-Antibody 
Cocktail for 5 minutes at 4°C to label the T cells, B cells, dendritic cells, and monocytes, followed by 
10 minute incubation at 4°C with a MicroBead Cocktail. The sample is then passed through a 
magnetic LS MACS column attached to a MACS separator (Miltenyi Biotech), as per the 
manufacturer’s instructions, to deplete the sample of the labelled cell types. Once again, the 
number of NK cells was determined using Trypan Blue and a Countess™ (Invitrogen). 
 
2.9.3 Estimation of cell population purity by flow cytometry 
 
2 x 105 cells were stained for 45 minutes on ice with the following mouse anti-human monoclonal 
antibodies (eBioscience): anti-CD56 (APC), anti-CD16 (FITC), anti-CD14 (PerCP-Cy5.5), anti-CD3 
(Pacific Blue), and anti-CD19 (PE). An unstained sample was also included. Samples were washed 
with 1ml PBS and resuspended in 250μl PBS before processing on a BD Canto II Flow cytometer. 
Forward-scatter and side-scatter area were used to plot live cells by size and granularity, 






I used compensation beads (BD Biosciences) to compensate for spectral overflows during the flow 
cytometry. These were prepared as per the manufacturer’s instructions, with 1µl of an antibody – 
for each fluorochrome to be used - being incubated with one drop of both positive and negative 
compensation beads at room temperature for 10 minutes in 100µ 1%BSA/PBS. These compensation 
controls were processed first and the compensation between fluorochromes was automatically 
calculated by the BD FACS DIVA software before experimental samples were processed.  
 
2.9.5 Cell Viability Assay 
 
I used the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) to measure whether the 
Leukadherin-1 (dissolved in DMSO; LA1) drug had a detrimental effect on NK cell survival, compared 
with the DMSO control. Isolated NK cells were resuspended in Lymphocyte Growth Medium (LGM) 
at a concentration of 0.5 x106 cells/ml. The cells were split into two aliquots in a 12-well cell culture 
plate, and incubated with either 1:2000 (v/v) DMSO (Sigma) or LA1 (15mM; Merck Millipore) for 30 
minutes at 37°C. These samples were then further split into 100µl (=50,000 cells) aliquots in a 96-
well plate and incubated overnight at 37°C with one of three conditions:  
 
 no further stimulus  
 1µl of IL-12 (10µg/ml) and 1µl of IL-15 (30µg/ml) 
 1µl of IL-12 (10µg/ml) and 1µl of IL-18 (10µg/ml).  
 
Each condition was run in quadruplicate. At 24 hours, the 96-well plate was removed from the 
incubator and equilibrated to room temperature before adding 50µl of the CellTiter-Glo® Reagent 
to the medium containing cells. Cell lysis was induced with an orbital shaker for three minutes, and 
an Orion II luminometer (Berthold) was used to read the luminescence of the samples with a one 
second measurement time. A two-tailed unpaired t-test was used to compare the luminescence 






2.9.6 Monokine activation of NK cells 
 
NK cells were plated at a concentration of 1 x 106/ml in Lymphocyte Growth Medium (LGM) in 12-
well plates and incubated for 30 minutes with 0.5µl/ml of either LA1 (15mM) or DMSO (vector 
control). Following this, 2 x 105 cells (=200µl) were plated in wells of a 96-well plate for cytokine 
stimulation. Combinations of either IL-12 (10µg/ml) and IL-15 (30µg/ml), or IL-12 and IL-18 (10µg/ml) 
were used, with 2µl of each (=1:100 v/v) added to the cell suspension. Two samples (one with DMSO 
and the other with LA1 pre-treatment) had no cytokines added and were used as non-activated 
controls (see 2.10.3 and 2.10.4.2). Cells were incubated at 37°C for various time points (see Chapter 
5). Cells were fixed with 200μl 4% PFA for 10 minutes at room temperature and then washed with 
2ml 1% BSA/PBS and spun at 800g for 5 minutes; this was repeated three times. 
 
2.9.7 Cell surface and intracellular staining 
 
 In order to differentiate between the NK cell subsets, the fixed cells  were resuspended in 100µl 1% 
BSA/PBS and stained with 1µl of a Pacific Blue conjugated anti-CD56 monoclonal antibody 
(Biolegend) for 45 minutes, protected from light, at room temperature. Following this, cells were 
permeablised with ice-cold methanol-based PermBuffer III (BD Biosciences) on ice for 30 minutes. To 
remove any residual methanol, cells were washed with 2ml 1% BSA/PBS, and centrifuged at 800g for 
5 minutes; this was repeated three times. The NK cells were resuspended in 100µl 1%BSA/PBS and 
stained with 5μl of PhosFlow antibodies  (BD Biosciences) – specific for phosphorylated intracellular 
signalling molecules (Table 2.5) - for one hour, protected from light, at room temperature. No 
isotype controls were used in this experimental design; instead, the non-activated cells (see 2.10.2) 
stained with the anti-phospho antibodies (Table 2.5) were used as negative controls for the levels of 












Table 2.5 Summary of monoclonal antibodies used in the PhosFlow assays to measure NK cell 
signalling. 
Antibody Epitope Mouse Isotype 
Alexa488 anti-pSTAT3 pY705 IgG2, k 
Alexa647 anti-pSTAT4 pY693 IgG2b, k 
Alexa647 anti-pSTAT5 STAT5A pY694 and 
STAT5B pY699* 
IgG1, k 
Alexa488 anti p-p38 pT180/pY182 IgG1, k 
*see Table 5.1  
 
2.9.8 Flow Cytometry and Analysis 
 
Samples were processed on a BDCanto II Flow cytometer with FACS DIVA software (BD Bioscience). 
The population of live NK cells were identified and gated by size and granularity using the forward- 
and side-scatter area voltages. A total of 30,000 events were recorded within this gate. I later used 
FlowJo (v.7.6.4) for the quantitative analysis. Firstly, by plotting forward-scatter area against 
forward-scatter width, I was able to isolate singlet cells and discount events that appeared to be 
doublet cells (Figure 2.2B). I used a side-scatter area/Pacific Blue scatter plot to identify the 
CD56brught population (Figure 2.2C). I recorded the median fluorescence of each of the fluorochromes 
used for both total NK cells and the CD56brught population. The fold-change was calculated with the 
following equation, where MFI is the median fluorescence intensity. 
 
             
                 
          
 
 
I used GraphPad (Prism) to test the difference in median fold-change, using a Willcoxon’s matched 






Figure 2.2 Identification of NK cell subsets by flow cytometry 
Isolated NK cells as viewed using FlowJo following analysis on a BD CANTO II. A) The NK cell 
population is clustered using forward- and side-scatter area plot. B) Singlet NK cells are isolated by 
plotting forward-scatter area against forward-sctater width. Recorded events with a large width:area 
ratio are likey to be doublet cells and are therefore excluded. C) NK cells can be further separated 
into two subsets based on their CD56 expression. A Pacific Blue-conjugated anti-CD56 antibody was 




2.10 FCGR2B-I232T genotyping 
 
Due the high degree of genomic identity between FCGR2B and FCGR2C, it was necessary for the 
reverse primer to be situated in intron 6, in order to ensure FCGR2B specificity. The PCR product was 
therefore 3Kb in length. I amplified 20ng of DNA using the SequalPrep™ Long-range PCR kit 
(Invitrogen) with 1unit of Hot Star Taq and 5pmoles of forward and reverse primers, as specified in 
Appendix A, in a total volume of 10μl. I used a nested forward primer (5’- 
CTGCAGAAGTGAGTGACTCA -3’) for the sequencing reaction, which is located 170bp upstream of the 
I232T variant (Chr1:161643798; hg19) and allowed reliable genotyping. Aside from this difference, 
the sequencing was carried out as stated in section 2.4.  
 
2.11 Paralogue Ratio Test (PRT)  
2.11.1 Theory 
 
This PCR-based technique relies upon small sequences of genetic homology between a region of the 
copy number variability (region of interest) and an independent non-copy number variable region of 
the genome (Armour et al. 2007). PCR primers are designed to give two products of slightly different 
sizes – one from the variable region and one from the independent control region – and are labelled 
on the 5’ end with a fluorescence dye. This design allows the PCR products to be size-separated by 
electrophoresis on an Applied Biosystems genetic analyzer, and visualised by Genemapper software 
(Applied Biosystems). The areas under the two peaks –which are relative to the amount of PCR 
product obtained - are compared within each sample to estimate the copy number of the variable 
region of interest. This technique has been applied to multiple genomic loci to measure CNV 
(Machado et al. 2013; X.-J. Zhou et al. 2012; Fernando et al. 2010). 
 
2.11.2 FCGR3B CNV 
 
Due to the high degree of sequence identity between FCGR3A and FCGR3B (see Introduction), the 
PRT primer pair amplify products of the same size (67bp) from both FCGR3A and FCGR3B; therefore 
the ratio between the variable (chromosome 1) and control (chromosome 18) region is 
representative of the total FCGR3 copy number. A second PCR-based assay is needed, called the 
Restriction Enzyme Digest Variable Region (REDVR), in order to differentiate between the two copy 




The PCR primers, the reverse of which is labelled with a VIC fluorescent tag (Appendix A6.2), amplify 
182bp regions of both FCGR3A and FCGR3B, containing a sequence variation between the two 
genes. The FCGR3A fragment contains a Taqα1 restriction enzyme cut site, giving products of 134bp 
(and 48bp), whereas FCGR3B does not. This enables differentiation between the two genes, and the 
absence of the larger, uncut product indicates the complete absence of FCGR3B (Figure 2.3). Thus 
the combination of the ratio between FCGR3: control (PRT), together with the FCGR3A:FCGR3B 
(REDVR) ratio enables accurate copy number calling of both FCGR3 genes (Hollox, Detering, and 
Dehnugara 2013). 
 
2.11.3 Measuring FCGR3A and FCGR3B copy number 
 
10ng of DNA was amplified with 0.5μM forward and reverse (FAM or HEX labelled) primers and 
0.5units of Taq polymerase (Qiagen), in a total volume of 10μl, as specified in Appendix A. The assay 
was run in duplicate on 96-well plates, one with a reverse primer fluorescently labelled with FAM 
and the other with HEX. This differential fluorescent labelling of the PCR primers enabled the pooling 
of the PRT products, and for mean values to be used in further analysis. 1μl of each FAM and HEX 
labelled PRT PCR product, plus 0.15μl 400HD ROX™ size standard, was added to 10μl of formamide 
(Sigma) and denatured at 95°C for 3 minutes. The PRT assay yields products of 67 and 72bp from 
chromosome 1 and chromosome 18, respectively. Peak area ratios were used to estimate a total CN 
for FCGR3A plus FCGR3B against the non-CNV region on chromosome 18.  
 
 
10ng of DNA was amplified with 0.5μM of each of the primer and 0.5U of Taq polymerase (Qiagen), 
in a total volume of 10μl (Appendix A). 2μl of the PCR product was digested with 2.5U Taqα1, in a 
total volume of 10μl, for 4 hours at 65°C. 1.4μl of the Taqa1-digested REDVR product, plus 0.15μl 
400HD ROX™ size standard, was added to 10μl of formamide and denatured at 95°C for 3 minutes. 
 
 
2.11.4 Genemapper Analysis 
 
Each 96-well plate contained seven positive controls of varying copy numbers, and a water negative 
control. Plates were repeated if the positive controls gave unexpected results. Samples were 
analysed by electrophoresis on an Applied Biosystems genetic analyser and Genemapper (Applied 




The VIC-labelled REDVR products gave peak areas at 134 (digested – FCGR3A) and 182 bp 
(undigested – FCGR3B) and were used to generate FCGR3A:FCGR3B ratios. FCGR3A CN was not used 
in further analysis. 
 
2.12 Statistical Analyses 
 
FCGR2B-I232T genotype and allele frequencies were compared between cases and controls by Chi-
squared tests or Fisher’s exact tests, where appropriate, using GraphPad Prism 5. An interaction 
between FCGR2B-I232T and FCGR3B-CNV was tested for by fitting an additive logistic regression 
model (SLE status as the outcome) using the statistical computing language R. David Morris (King’s 

























Figure 2.3 Measuring FCGR3B copy number using the PRT assay 
Images are representative of data as visualised using Genemapper software. A) FAM-labelled PRT 
products from FCGR3 (67bp; left histogram) and non-copy number variable (CN in diploid 
genome=2) reference locus on chromosome 18 (72bp; right histogram). The ratio of the areas under 
the histograms are used to calculate the number of FCGR3 copies, per genome, compared with the 
non-copy number variable region (CN=2). B) VIC-labelled REDVR products following Taqα1 digestion. 
Digested FCGR3A products (134bp; left histogram) and undigested FCGR3B (182bp; right histogram) 
products are seen. The ratio of the areas under the histograms are used to calculate the copy 
number of FCGR3A and FCGR3B per genome. 
 














Altered protein expression has been shown to be the underlying mechanism through which disease-
associated variations manifest their effect, the extreme examples of which being gene-dosage 
effects of copy number variable loci resulting in altered mRNA and protein levels (Groth et al. 2010; 
Willcocks et al. 2008). Additionally, showing that a polymorphism does not affect protein expression 
is invaluable in further establishing the functional effects of a non-synonymous variation, allowing a 
comprehensive interpretation of functional assays.  
 
The cell surface expression of CR3 requires the non-covalent binding of CD11b and CD18. It is 
therefore possible that a missense variant within CD11b - such as the SLE-associated R77H - could 
affect the coupling of these two polypeptides resulting in reduced expression. Protein-coding 
mutations in CD18, which cause Leukocyte Adhesion Deficiency (LAD) diseases, have been shown to 
affect the ability of CD18 to pair with CD11 polypeptides (Shaw et al. 2001). Therefore, by measuring 
the cell surface expression of CR3 between genotypic groups, the R77H effects on the CD11b-CD18 
polypeptide partnership can be interpreted. 
 
In addition, by investigating CR3 expression dependent on R77H genotype, it is possible to 
determine whether or not the 77H variant (rs1143679) is in tight LD with a variant in the regulatory 
region of ITGAM which may affect gene expression. For instance, if the 77H variant was found on a 
haplotype that reduced ITGAM gene expression resulting in lower cell-surface expression of CR3, this 
could lead to the overestimation of the magnitude of detected functional effects directly attributed 
to the missense polymorphism. Likewise, elevated cell-surface expression could result in an 
underestimation of any detectable functional impairment. It is therefore essential to delineate 
potential effects of expression alterations before interpreting functional assays with confidence. 
 
As discussed in section 1.4.2, CR3 undergoes conformational changes in response to allosteric 
activation (Hynes 2002). The same conformational changes occur under both mechanisms, with the 
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extension and straightening of the extracellular domain, and separation of the CD11b and CD18 
cytoplasmic tails; ultimately these conformational changes enable high-affinity ligand-binding (Luo, 
Carman, and Springer 2007). It is plausible that a missense variant could alter the 3D structure of a 
protein such that conformational changes are impaired. Therefore, in addition to absolute protein 
levels, it is possible that a histidine residue at position 77 of CD11b could affect the folding or 
extension of the CR3 protein.  Upon receptor activation, an antibody (CBRM1/5) epitope is revealed 
within the I-domain of the CD11b polypeptide, allowing the relative levels of activation to be 
estimated by flow cytometry (Diamond and Springer 1993). 
 
As detailed in the section 1.4.4, the optimal expression, under both steady state and inflammation, 
and conformational changes of CR3 on neutrophils and monocytes enables a fine-balance of 
inflammatory responses. Indeed there is evidence to suggest that  CR3 expression and activation 
determines the capabilities of neutrophils to phagocytose certain microbes, such as B. pertussis 
(Mobberley-schuman and Weiss 2005). Through use of two anti-CD11b monoclonal antibodies - one 
without conformation specificity (clone ICRF44) and another specific with specificity for the active 
conformation (clone CBRM1/5) - I measured the effects of the R77H polymorphism on both the cell 
surface expression and activation of CR3, respectively, under resting and activated conditions, by 
flow cytometry.  
 
3.2 Results 
3.2.1 Identification of neutrophils and monocytes by flow cytometry 
 
I used fresh, leukocyte-enriched, heparinized whole blood from healthy donors (n=20) of Northern 
European ancestry from the Twins UK NIHR Bioresource (Methods 2.1.1). Individuals were chosen 
for their homozygosity at rs1143679, and were processed as pairs of opposing genotypes - 
homozygous WT (R77) and homozygous 77H.  
 
Neutrophils are large, granular cells, which enables easy identification by flow cytometry, without 
the use cell surface markers specific antibodies. By plotting light forward-scatter (FSC) and side-
scatter (SSC), which separate cells by size and granularity, respectively, the large neutrophil 
population forms a separate cluster respective to other leukocytes (Figure 3.1A). 
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The unique cell-surface expression of CD14 allows monocytes to be distinguished from other 
leukocytes of the same size during a whole blood FACS by staining the sample with a fluorescently 
labelled (in this instance PerCP-Cy5.5) anti-CD14 antibody, (Figure 3.1B). I did not distinguish the 
monocytes according to their CD14/CD16 subsets, but instead analysed them as a whole population. 




Figure 3.1 Identification of neutrophil and monocyte populations by flow cytometry 
A) Forward- (x-axis) and side-scatter (y-axis) was used to separate the neutrophil population within a 
leukocyte-enriched whole blood sample, prior to CR3 expression analysis, as indicated by the 
polygon gate. B) A PerCP-Cy5.5 conjugated anti-CD14 antibody was used to stain a leukocyte-
enriched whole blood sample. By plotting side-scatter (y-axis) against PerCP-Cy5.5 (x-axis) the CD14+ 
monocyte population can be distinguished from other leukocytes of the same size prior to CR3 





3.2.2 Cell surface expression of CD11b on resting ex vivo monocytes and neutrophils 
 
I measured absolute cell surface expression (Figure 3.2) and percentage of CD11b in its active 
conformation (Figure 3.3) on resting monocytes and neutrophils. Using a paired t-test, there was no 
significant difference in the expression of CD11b on resting monocytes (P=0.25) and neutrophils 
(P=0.33; Figure 3.2), nor was there a significant difference in the percentage of CD11b in its active 
conformation on resting monocytes (P=0.16) and resting neutrophils (P=0.86; Figure 3.3), between 
the homozygous genotype groups. I observed low levels of CBRM1/5 positive cells under resting 
conditions, indicating that the experimental protocol was conducted under sterile conditions that 
did not significantly activate the leukocytes.  
 
3.2.3 Cell surface expression of CD11b on PMA-stimulated ex vivo monocytes and neutrophils 
 
Phorbol myristate acetate (PMA) is known to upregulate CR3 expression and is commonly used to 
study its activation (Wright and Meyer 1986; Ma, Plow, and Geng 2004). I measured absolute cell 
surface expression (Figure 3.2) and percentage of CD11b in its active conformation (Figure 3.3) 
following PMA-stimulation for 10 minutes at 37°C (Methods 2.2). I observed a ~10-fold increase in 
CD11b cell surface expression on both monocytes and neutrophils, compared with resting cells, 
irrespective of genotype (Figure 3.2). Once more, using a paired t-test, no significant differences 
between genotype groups were observed for CD11b expression on stimulated monocytes (P=0.97) 
and neutrophils (P=0.42; Figure 3.2), nor were there significant differences in the percentage of 
activated CD11b on stimulated monocytes (P=0.70) and neutrophils (P=0.47; Figure 3.3). 
 
3.2.4 Increased CD11b expression in one individual under resting conditions 
 
There is one individual - from the 77H genotype group - who repeatedly showed higher expression 
of CD11b on both resting neutrophils and monocytes, as seen in Figure 3.2. I attempted to identify a 
variation in the promoter region of the ITGAM gene by sequencing ~500bp upstream of the start 
codon (Methods 2.3). The reverse primer was located in exon 1 of ITGAM to ensure good sequencing 
coverage upstream of the coding region of the gene. I additionally amplified and sequenced the 
genomic DNA from another healthy control who had not shown elevated expression levels of CD11b 




Figure 3.2 Cell surface expression of CD11b on neutrophils and monocytes under resting and 
activated conditions 
Leukocyte-enriched whole blood from healthy volunteers (n=20) of either R77 (WT) or 77H 
homozygous genotypes was incubated with PE-conjugated anti-CD11b (clone ICRF44) and Per-CyP-
conjugated anti-CD14 antibodies and analysed by flow cytometry. No significant difference in cell 
surface expression of CD11b was seen between genotypic groups for either neutrophils (left panel) 
or monocytes (right panel), under resting (upper panel) or PMA-stimulated (lower panel) conditions, 
as measured by MFI and compared using a paired two-tailed t-test. 
 


































































































Figure 3.3 Percentage of CD11b present in active conformation on neutrophils and monocytes 
under resting and activated conditions 
Leukocyte-enriched whole blood from healthy volunteers (n=20) of either R77 (WT) or 77H 
homozygous genotypes was incubated with APC-conjugated activation specific anti-CD11b (clone 
ICBRM1/5) and Per-CyP-conjugated anti-CD14 antibodies and analysed by flow cytometry.  No 
significant difference in percentage of activated CD11b was seen between genotypic groups for 
neutrophils (left panel) or monocytes (right panel), under resting (upper panel) or PMA-stimulated 
(lower panel) conditions, as measured by MFI and compared using a paired two-tailed t-test. 
 














































































































































As discussed in section 1.4.2, leukocytes yet to undergo activating stimuli have low densities of cell 
surface receptors that are involved in inflammatory processes, such as CR3 (Ley 2002). Large 
intracellular pools of such receptors are stored in secretory vesicles and are available for immediate 
up-regulation of cell surface expression following appropriate activating signals. Sufficient regulation 
of this function is of paramount importance to the host organism to avoid leukocyte hypersensitivity 
and subsequent tissue damage. 
 
My data provide strong evidence that the R77H missense variant does not affect CR3 expression on 
the cell surface of resting ex vivo monocytes and neutrophils (Figure 3.2, Figure 3.3), suggesting that 
the SLE-associated polymorphism neither affects the absolute levels of translated CD11b 
polypeptide, nor the heterodimer formation between CD11b and CD18. Furthermore, R77H did not 
affect the up-regulated cell surface expression of CR3 on either cell type following PMA stimulation 
(Figure 3.2).In this study, an antibody specific for an I-domain epitope, which is revealed only when 
CR3 adopts its active conformation state (clone CBRM1/5) (Diamond and Springer 1993), was utilised 
to measure the effects of the R77H polymorphism on the allosteric activation of CR3 (Hynes 2002). 
The R77H variant is located in the β-propeller domain of CD11b, which is not thought to be a direct 
binding site for any of the CR3 ligands. However, as this transmembrane protein carries cell signals 
and, in doing so, alters its conformation, the R77H variation could affect the protein’s cell signalling 
leading to impaired function. I observed no significant difference between the two homozygous 
genotype groups, suggesting that the R77H polymorphism does not affect the ability of the CR3 
receptor to extend into the fully active conformation on monocytes and neutrophils (Figure 3.3); a 
necessary change needed for high-affinity ligand-binding.  
 
My work alone does not shed-light on whether or not ITGAM gene regulation is altered by the 
haplotype on which 77H is found in individuals of Northern European ancestry. However, a 
colleague, Dr Barbara Fürnrohr, used a quantitative PCR (qPCR) method to compare the relative 
mRNA levels in ex vivo PBMCs and monocytes from WT homozygous (n=14) and R77H heterozygous 
(n=9) healthy controls. No significant difference was observed between genotype groups (Rhodes et 
al. 2012). Together these data provide strong evidence that there is no expression difference, on an 




Since this work was carried out, two additional studies have reported no genotypic difference in the 
cell surface expression, or activation, of CR3 on ex vivo monocytes, macrophages, neutrophils, and 
dendritic cells of healthy volunteers (Y. Zhou et al. 2013; Fossati-Jimack et al. 2013). Additionally, in 
vitro studies report no difference in expression levels between WT and 77H transfected cells, 
indicating that the CD11b/CD18 pairing is not affected by this non-synonymous variation 
(MacPherson et al. 2011). 
 
The use of healthy subjects, as opposed to individuals with disease, is beneficial in studying the 
effects of genetic variants on ex vivo cells as potential confounding factors are reduced (such as drug 
treatment). Most recently however, a study reported a R77H-dependent reduction of CR3 cell 
surface expression on, and CD11b mRNA levels in, ex vivo monocytes of SLE patients (Maiti et al. 
2014). There are, I believe, potential issues with the methodologies applied in this study. The 
majority of the samples were SLE patients (n=53), and a negative correlation is seen with CR3 cell 
surface expression and rs1143679 minor allele count (cell surface expression is highest for 
homozygous WT (GG) and lowest for homozygous risk (AA)). Three samples from heterozygous 
healthy individuals were also included in the analysis, and the authors conclude that this is sufficient 
to discount the possibility of confounding factors such as drug use (Maiti et al. 2014). Additionally, 
CD14 positive selection was applied to isolate monocyte before allelic imbalance assays were 
performed. CD14 is a co-receptor for TLR ligation, therefore the monocytes could be activated 
during isolation (Noubir, Hmama, and Reiner 2004). As discussed in section 1.4.4, there is evidence 
that CR3 interact with the CD14 on the cell surface of monocytes, which adds further complexity to 
the interpretation of their results (Hawley et al. 2011). In addition, some of the electropherograms 
used to calculate relative allelic expression appear to show a peak for the ancestral G nucleotide 
only, and the authors claim this to be extreme allelic imbalance. However, an alternative 
explanation, of course, is preferential allelic amplification or genotyping error and this is not clearly 
disproved in the manuscript (Maiti et al. 2014). My work demonstrates no genotypic difference in 
CR3 expression following PMA activation. It is, however, possible that genotypic differences are 
present following activation through alternative stimuli (Maiti et al. 2014). More work is needed to 
establish whether or not the differential expression of CR3 on ex vivo cells from SLE patients is 




A recent descriptive study reports lower ITGAM mRNA levels in PBMCs from SLE patients compared 
with healthy controls (M. Zhou et al. 2013). Additionally, they found significant decreases in cell 
surface expression of CD11b on T cells, monocytes, and neutrophils, and correlations with disease 
activity were observed (M. Zhou et al. 2013). The genotypes of these individuals have not been 
considered; indeed they also measured FCGR3A (CD16a) expression without considering the copy 
number variation at this locus. It has previously been reported that neutrophils from SLE patients 
showed significantly elevated levels of cell-surface CR3, as measured by an anti-CD11b antibody, 
compared with healthy controls, and furthermore, that CR3 expression correlated with disease 
activity (Buyon et al. 1988). Even though these two studies are contradictory, it is likely that disease 
status and, in particular, disease activity alter the expression levels of immune complex receptors. 
However, the results of my work, and that of others (Y. Zhou et al. 2013; Fossati-Jimack et al. 2013), 
demonstrate that the R77H polymorphism does not affect CD11b expression in healthy controls, 
suggesting that altered CD11b expression is not a mechanism through which the ITGAM association 
is explained. Here we see an example of how genetic analyses can help delineate between cause and 
effect of disease status; observations of altered CD11b expression are likely be products of, and not 
a mechanism contributing to, immune dysregulation.  
 
CR3 activation following PMA stimulation, as measured here, is a model of integrin ‘inside-out’ 
activation (section 1.4.2). My results therefore suggest that the R77H variant does not impact on the 
ability of CR3 to respond to the ‘inside-out’ transmission of cellular activation signals. TNF, INF-γ, and 
IL-8 are all reported to increase CR3 expression and activation (Mobberley-schuman and Weiss 2005; 
Ley 2002). Given the results reported here, I would not predict R77H to impact on the up-regulation 
and activation of CR3 following stimulation by these pro-inflammatory cytokines. However, the 
R77H-dependent impairment of CR3 function suggests that the missense variant does indeed affect 
‘outside-in’ signalling (MacPherson et al. 2011). These results cannot be explained by ligand-binding 
impairment as no difference in ligand association is observed, but are instead attributed to defective 
downstream signalling transmission (Rhodes et al. 2012).  
 
One individual showed high CD11b expression on both resting neutrophils and monocytes, and this 
was repeatedly replicated (data not shown). It is possible that this is due to a variation in a 
regulatory region of ITGAM. However, through capillary sequencing, I did not detect a notable 
variation in the 500bp upstream region of the ITGAM start codon. It is probable that a variation is 
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present beyond the region I surveyed, or indeed that a variation is present in the regulatory region 
of ITGB2 (encoding CD18). If the variation is indeed located in the ITGB2 gene, then it is possible that 
a higher expression of other CD18 integrins would be observed also; something I did not measure. 
Given the complexities of gene expression regulation, it was hard to foresee the extent to which I 
would need to extend the search through sequencing. Additionally, given the individual’s CR3 
expression on PMA-stimulated cells was not as dramatically different to other individuals within the 
study, nor were there differences in percentage of CR3 proteins present in the active conformation 
(Figure 3.3), it is unclear how much of a biological impact this observed higher expression of low-
affinity CR3 on resting cells would have on neutrophil and monocyte function. For these two 
reasons, I decided pursuing the search for putative – possibly even novel - genetic variations was not 























For most complex diseases, as with SLE, the amount of unexplained genetic variance following very 
large GWA studies is higher than initially anticipated under the common disease-common variant 
(CDCV) hypothesis (Reich and Lander 2001; Manolio et al. 2009; So et al. 2011). As discussed in 
section 1.2.2, rare variants with larger effect sizes than the average disease-associated 
polymorphism (OR≥2), but present at frequencies that fall below the detectable threshold of most 
GWA studies (MAF<5%), is one of multiple hypotheses which address this problem of ‘missing 
heritability’ (Pritchard 2001; Pritchard and Cox 2002; Eichler et al. 2010).  Although these variants 
are individually rare, they are collectively common, therefore may make a significant contribution to 
disease risk on the population level and many studies have now successfully identified additional 
rare variants in GWAS-associated loci (Torgerson et al. 2012; Rivas et al. 2011). Given the robust 
associated of the non-synonymous polymorphism R77H with SLE, ITGAM was a great candidate gene 
for resequencing in a patient cohort.  
 
Through resequencing 24Kb of the ITGAM gene in 73 SLE patients, Ellen Thomas (Imperial College 
London) successfully identified two non-synonymous rare variants, F941V and G1145S.  In this 
chapter I present the continuation of this work. Firstly, I conducted follow-up genotyping of both 
rare variants in SLE cohorts to estimate their frequency. Secondly, I assessed the functional effects of 
these variants on CR3 function by utilising a robust in vitro model of phagocytosis. This assay had 
previously been used to demonstrate the under-functioning effects of the R77H polymorphism 
(MacPherson et al. 2011; Benjamin Rhodes et al. 2012).  
 
In addition, I used the same in vitro model to ascertain whether the CD11b-A858V polymorphism 
(rs1143683) had any deleterious impact on the phagocytic capabilities of CR3, as there has been 
speculation of a secondary independent SLE association with this non-synonymous polymorphism 
(W. Yang et al. 2009), as discussed in section 1.3.1. Since there is precedence  for the presence of 




4.2.1 Two novel non-synonymous variants discovered through ITGAM resequencing 
 
24kb of the ITGAM locus, including all exons and intron-exon boundaries, was resequenced at high-
coverage (x105) on the 454 Next Generation Sequencing (NGS) platform in 73 SLE patients of 
European ancestry (Methods 2.5.1). The 73 cases used in this resequencing study met the ARC 
classification criteria for SLE, but were not chosen for any further sub-phenotypic reason. 
 
Seventeen candidate rare variants within ITGAM were identified from this resequencing (Methods 
Table 2.1). However, through capillary sequencing I was only able to confirm two of these putative 
variants, which highlights the need to address potential false positives in NGS data. F941V 
(chr16:31340577) and G1145S (chr16:31343001) were each confirmed in one patient sample each - 
88:2.1 and 50:2.2, respectively (Figure 4.1).  
 
I utilised a large-scale publicly-available sequencing project datasets to screen ITGAM on the 
chromosomes of healthy controls of European ancestry. Neither variant, F941V nor G1145S, is 
described in the 8600 European-American chromosomes of The National Heart Lung and Blood 
Institute’s (NHLBI) Exome Variant Server (EVS; http://evs.gs.washington.edu/EVS/). This database 
reports high sequence coverage across the ITGAM regions containing the rare variants (Table 4.1) 
and for this reason is a comparable control dataset for our sequencing data. Therefore, both variants 
are novel. It is worth noting that neither variant is found in the African-American cohort also 










Figure 4.1 Validation of ITGAM rare variants by capillary sequencing 
A) Forward sequence of ITGAM exon 24 from patient 88:2.1 as visualised by BioEdit software 
following capillary sequencing. The solid arrow highlights the T/G heterozygous peak encoding the 
F941V rare variant (codon change = TTC  GTC). B) Reverse sequence of ITGAM exon 30 from 
patient 50:2.2 as visualised by BioEdit software following capillary sequencing. The solid arrow 
highlights the C/T heterozygous peak encoding the G1145S rare variant (codon change = GGT  
AGT), and the dotted line highlights G/A heterozygous peak encoding the P1146S polymorphism 







4.2.2 In silico analyses of F941V and G1145S 
CD11b codons 941 and 1145 are located in the membrane-proximal extracellular domain and the 
short cytoplasmic tail of the protein, respectively (Figure 4.2).  I used MultAlin (Corpet et al. 1988; 
http://multalin.toulouse.inra.fr/multalin/) to compare the protein sequences of the four human 
CD11 molecules that pair with CD18 as part of the β2 integrin family (Figure 4.3). The four proteins 
CD11a, CD11b, CD11c and CD11d are encoded by ITGAX, ITGAM, ITGAL, and ITGAD, respectively.  





extracellular domain, is conserved across all four polypeptide sequences. The Glycine (G) residue at 
CD11b codon 1145 is not shared with any of the other three CD11 proteins. In fact there is no 
homology at this relative position amongst any the CD11 amino acid sequences. The short 
cytoplasmic tails of the CD11 molecules vary in length and sequence, and the differences observed 
are likely to be crucial for their varying functions, and/or intracellular signalling properties (Hynes 
2002).  
 
I estimated the pathogenicity of F941V and G1145S using PolyPhen-2 (Adzhubei et al. 2010) and SIFT 
(Kumar, Henikoff, and Ng 2009). PolyPhen-2 categorises mutations as ‘benign’, ‘possibly damaging’ 
or ‘probably damaging’ based on pairs of false positive rate (FPR) thresholds. SIFT predicts variants 
to be deleterious given an output value <0.05 (Methods 2.7.2). F941V was predicted to be 
deleterious, and G1145S was predicted to be benign, by both algorithms (Table 4.1). 
 
 
Table 4.1 Genomic details and pathogenicity predictions of ITGAM rare variants. 
Genomic location, PolyPhen-2 and SIFT predictions of pathogenicity of F941V and G1145S, and 








F941V Exon 24 16:31340577 58.2 ±12.1 Probably damaging (1.00) Damaging (0) 












Figure 4.2 ITGAM transcript, CD11b primary protein domains and CR3 protein. 
 
A) ITGAM genomic organisation showing relative positions of common polymorphisms (R77H, 
M441T, A858V), and novel rare variants (F941V, G1145S). B) Primary protein domains of CD11b and 
the relative location of the missense variants. The β-propellor domain is shown in dark blue; the 
ligand-binding I-domain is shown in green; light blue represents the other extracellular domains; the 
transmembrane domain is shown in yellow and the short cytoplasmic tail is represented in orange. 
C) A cartoon diagram of the CR3 protein (Protein domain ratios = extracellular: transmembrane: 
cytoplasmic = 1:6:6). The same colours as b) are used to represent the various domains; CD18 is 
shown in light purple. Asterisks are used to indicate the position of missense variants used in the 






Figure 4.3 Mutalin alignment of human CD11 amino acid sequences 
CD18 pairs with CD11b, CD11a, CD11c and CD11d, and together these make up the β2 integrin 
family. The four CD11 protein sequences (encoded by ITGAM, ITGAX, ITGAD and ITGAL) were aligned 
using MutAlin software. The numbers indicate the CD11b codons and all other sequences are aligned 











4.2.3 Follow-up genotyping in larger SLE cohorts 
4.2.3.1 F941V 
 
F941V was further genotyped in 2107 SLE cases of European ancestry; 1762 were genotyped on an 
Illumina Custom 384 Chip in the University of Uppsala, Sweden, as part of Prof. Tim Vyse’s GWAS 
replication study (Methods 2.6.2), and an additional 345 samples I genotyped using SSP-PCR (Figure 
4.4; Methods 2.6.1). The F941V variant was not observed again in the SLE cohort. I was, however, 
able to identify the patient’s mother (80:1.2) and sibling (88:2.2) as heterozygous for F941V. Neither 




G1145S did not pass QC analysis following the Illumina Chip genotyping, possibly due to its close 
proximity (3bp) to the common polymorphism P1146S (as seen in Figure 4.1b). I therefore used 
capillary sequencing to genotype this variant in 949 SLE cases of European ancestry (Methods 2.6.3). 
This variant was not observed again in these additional cases. None of the family members of 
patient 50:2.2, for which DNA was available, carried the G1145S variant. However the father’s DNA 
was not available for genotyping. 
 
 
Figure 4.4 SSP-PCR genotyping of the F941V variant by agarose gel electrophoresis 
The presence of the 3rd amplicon (151bp) indicates 88:2.1 (SLE patient; Lane 6) and 88:2.2 (sibling; 
Lane 8) are heterozygous for F941V. All other samples are WT homozygous as determined by the 
absence of the lower size band. Hyper Ladder IV (Lane 1) and water negative control (Lane 4) are 





4.2.4 In vitro analyses of rare and common variants 
 
I included two common polymorphisms M441T (rs11861251) and A858V (rs1143683), which are in 
low (r2=0.017) and relatively high (r2=0.551) LD, respectively, with R77H in European populations, in 
the in vitro analyses. The LD scores were calculated with 1000 Genomes Pilot 1 CEU data set using 
SNAP Pairwise LD (http://www.broadinstitute.org/mpg/snap/ldsearchpw.php). A858V has 
previously been suggested to be a secondary independent association within ITGAM in a Thai 
population (W. Yang et al. 2009) and therefore I wished to ascertain whether there was functional 
evidence to support this. I envisaged M441T as a negative control as there is no genetic evidence to 
suggest this is associated with SLE.  
 
I successfully introduced each of the four variants – F941V, G1145S, M441T, and A858V – 
individually into a CD11b-pcDNA3.1(-) plasmid vector by site-directed mutagenesis (Methods 2.8.1). 
Figure 4.5 shows the mutated ITGAM sequences from each plasmid, as visualised using BioEdit 
software following capillary sequencing, compared with the WT sequence as taken from UCSC. I 
used these plasmids, along with a CD18-pcDNA3.1(-) plasmid, to transiently co-transfect COS-7 cells 














Figure 4.5 ITGAM sequences following site-directed mutagenesis.  
UCSC sequences surrounding F941, G1145, M441, and A858 of ITGAM and corresponding 













4.2.4.1 Effects of rare and common ITGAM variants on CR3 expression 
 
24 hours following transfection of the COS-7 cells, I measured CR3 expression using a PE-conjugated 
anti-CD11b (clone ICRF44) monoclonal antibody and compared the mean fluorescence intensity 
(MFI) of the CD11b positive cells (Methods 2.8.6). No significant difference in cell surface expression 
of CD11b was observed between WT (n=5, mean ± s.d.; 14445±6982) and M441T (15017±7993), 
A858V (12377±5130), F941V (14327±4358), or G1145S (12767±5028) CD11b transfected cells (Figure 
4.6), suggesting that none of the M441T, A858V, F941V, and G1145S variants affect the transfection 
efficiency, nor do they affect the non-covalent binding of CD11b to CD18.  The same is true for the 
R77H variant, as shown in Chapter 3 (Rhodes et al. 2012).  
 
Figure 4.6 Expression of CR3 in transfected COS-7 cells.  
The MFI of ICRF44-positive COS-7 cells are shown for WT and each of the four CD11b variants No 
significant difference in cell surface expression of CD11b was observed between WT (mean ± s.d.; 
14445±6982) and M441T (15017±7993), A858V (12377±5130), F941V (14327±4358), or G1145S 






4.2.4.2 Effects of rare and common ITGAM variants on iC3b binding 
 
To test whether the non-synonymous variants affected iC3b binding, I measured the ability of 
transiently transfected COS-7 cells to associate with iC3b-opsinized sheep red blood cells (sRBCiC3b) 
using an Association Index (Methods 2.8.8). No significant difference was observed when variant 
CD11b were compared with WT (paired t-test: M441T p=0.79; A858V p=0.69; F941V p=0.61; G1145S 
p=0.85), indicating that none of the four variants affect the iC3b binding ability of CR3 (Figure 4.7). 
Given that the four variants are located outside the iC3b-binding site of the protein (Diamond et al. 
1993), this was an expected result.  
 
 
Figure 4.7 Association of CR3-expressing COS-7cells with sRBCiC3b.  
Association Index = mean number of associated (internal and external) sRBCiC3b/100 COS-7 cells. No 







4.2.4.3 Effects of rare and common ITGAM variants on phagocytosis 
 
I compared the effects of CD11b variants on CR3-mediated phagocytosis of sRBCiC3b by comparing 
the Phagocytic Index (Figure 4.8) and Percentage Phagocytosis (Figure 4.9) of CD11b-variant 
expressing COS-7 cells to WT-CD11b COS-7 cells (Methods 2.8.8). F941V significantly impaired the 
Phagocytic Index (p=0.002; Figure 4.8) and the percentage phagocytosis (p=0.006; Figure 4.9), and 
the G1145S variant significantly impaired percentage phagocytosis (p=0.0232; Figure 4.8), when 
compared with the WT. The reduction in Phagocytic Index between G1145S and WT did not reach 
statistical significance at the 95% level (p=0.37). Neither of the two common polymorphisms, M441T 
and A858V, had an effect on the phagocytosis of sRBCiC3b as measured by the Phagocytic Index 
(Figure 4.8; M441T p=0.74; A858V p=0.92), and percentage phagocytosis (Figure 4.9; M441T p=0.70; 
A858V p=0.47). 
 
Figure 4.8 Phagocytosis of sRBCiC3b by CR3-expressing COS-7cells as measured by Phagocytic Index.  
Phagocytic Index = mean number of internal sRBCiC3b/100 COS-7 cells. F941V significantly impairs 
phagocytosis (p=0.002). No significant difference observed between WT and either common 





Figure 4.9 Phagocytosis of sRBCiC3b by CR3-expressing COS-7cells as measured by Percentage 
Phagocytosis.  
Percentage Phagocytosis = mean percentage phagocytosis/COS-7 cell. Both rare variants F941V and 
G1145S significantly impair phagocytosis (p=0.006 and 0.0232, respectively). No significant 













4.2.4.4 Comparison of under-functioning rare variants with R77H 
The COS-7 model was used by our group to demonstrate the deleterious effects of the SLE-
associated missense polymorphism, R77H, on iC3b-dependent phagocytosis (work carried out by, Dr 
Ben Rhodes; Rhodes et al. 2012). By using the percentage reduction in phagocytosis compared with 
WT (set to 100%) for each independent assay, I was able to compare my results to that of the 
previous R77H study (Figure 4.10). As seen here, G1145S (26%) has a comparable magnitude of 
effect to that of R77H (31%), whereas F941V (61%) has an even greater effect on phagocytosis. 
 
 
Figure 4.10 Percentage reduction in phagocytosis of CD11b variants compared with WT 
Comparison of the functional impact of the  two rare variants to that of the SLE-associated R77H 







































Through use of multiple cell models transfected to express CR3, and ex vivo monocytes/monocyte-
derived macrophages from healthy volunteers, the SLE-associated R77H variant has been shown to 
impair phagocytosis of iC3b-coated targets (Rhodes et al. 2012; MacPherson et al. 2011). In addition, 
the CR3-mediated  adhesion to iC3b, ICAM-1, and fibrinogen is significantly reduced by this variant 
(Rhodes et al. 2012; MacPherson et al. 2011). Adhesion, unlike ligand-binding, requires multiple 
downstream receptor functions, very much like phagocytosis (Cougoule et al. 2004). Ligand binding, 
however, by monocytes or neutrophils, is not affected by the R77H polymorphism (Rhodes et al. 
2012; MacPherson et al. 2011). It was concluded therefore that R77H affects the “outside-in” 
signalling of CR3 (MacPherson et al. 2011). 
 
In this chapter I have demonstrated the functional impact of two case-specific rare variants in 
ITGAM. These variants, F941V and G1145S, were identified through the resequencing of ITGAM in 73 
SLE patients of European ancestry. The in vitro model shows both these variants, G1145S and, more 
strongly, F941V impair CR3-mediated phagocytosis of iC3b-coated targets. The observed detrimental 
impact on protein function is of a similar (G1145S), or greater (F941V), magnitude to that of the 
common SLE-associated polymorphism R77H, which is associated with a 31% reduction in 
phagocytosis (Rhodes et al. 2012). Firstly, these data add further evidence for the coexistence of 
common and rare variants in genetic loci predisposing to the same disease biology, and secondly, 
they emphasise the role of under-functioning ITGAM variants in SLE pathogenesis. 
 
The targeted resequencing of loci harbouring disease-associated common polymorphisms has 
successfully identified novel rare variants in a number of other complex genetic diseases such as 
inflammatory bowel disease, psoriasis and asthma (Torgerson et al. 2012; Rivas et al. 2011; Jordan et 
al. 2012). Studies in schizophrenia (Need et al. 2012) and epilepsy (Heinzen et al. 2012) identified 
rare variants through whole-exome sequencing but failed to identify a single variant which reached 
study-wide significance despite large-scale genotyping in follow-up cohorts. In fact, the 
schizophrenia study reported that 23% of case-specific variants from the initial sequencing cohort 
were not observed again in the follow-up cohort (Need et al. 2012). As demonstrated by these two 
studies, individual rare variants may never reach statistical significance for disease association. In the 
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follow-up genotyping presented in this chapter, 2107 and 949 additional SLE cases were found to be 
wild-type for F941V and G1145S, respectively.  
 
Despite the lack of statistical evidence for a contribution of these rare variants to SLE, the functional 
assessment of these ITGAM variants demonstrates their contribution to disease biology. I was able 
to do this by utilising a robust functional assay that had previously proven successful in delineating 
the function of the common ITGAM R77H variant (Rhodes et al. 2012). Such in vitro studies are 
beneficial to study polymorphisms of interest in isolation from other confounding factors on ex vivo 
cells, particularly the presence of other receptors with similar ligand-specificity. COS-7 cells possess 
the ability to phagocytose, however they do not express endogenous phagocytic receptors. The 
introduction of phagocytic receptors through transfection therefore provides a robust model for 
phagocytosis without confounding factors (Caron 1998).  
 
It has been suggested that impaired phagocytosis is the main mechanism by which R77H confers risk 
to SLE (Fossati-Jimack et al. 2013). The G1145S variant had a comparable under-functioning effect 
(26%), whereas F941V had an even greater impact on phagocytosis (61%). It is likely, then, that these 
rare variants are contributing towards dysfunctional phagocytosis in the two patients in question. As 
discussed in section 1.1.2, the ‘waste disposal’ hypothesis is a central paradigm of SLE disease 
biology and refers to insufficient clearance of apoptotic cells by under-functioning of phagocytes 
(Gaipl et al. 2007; Pittoni and Valesini 2002; Herrmann et al. 1998). Apoptotic cells are opsonised 
with soluble ligands of phagocytic receptors, such as complement factors, enabling their effective 
recognition (Pittoni and Valesini 2002). Defective clearance of apoptotic cells leads to their 
accumulation and subsequent release of nuclear components. Through presentation by antigen-
presenting cells (APCs), such as dendritic cells (DCs), and exposure to cells of the adaptive immune 
system, this leads to the production of the characteristic autoantibodies to nuclear components 
(Kelley et al. 2010). 
 
This work does not contribute to the estimate of overall genetic variance explained for SLE, but it 
does add evidence to the functional importance of the ITGAM locus to SLE susceptibility. 
Furthermore, this work is another example of rare variants located in genetically-associated loci 
whose contribution to disease risk cannot be estimated by statistical models alone due to their 
extremely low frequencies. However, given the demonstrated functional impact of these variants, 
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their contribution to disease pathogenesis cannot be dismissed. In fact, a case report of a CR3 defect 
in an SLE patient has previously been assumed to be a result of a rare genetic variant (Witte et al. 
1993).  
 
Many studies of rare variants in complex diseases are concluding that such variation has negligible 
contribution to the genetic variance of complex diseases (Hunt et al. 2013). However, until 
additional methods of analysis are available, the contribution of rare variants to complex diseases 
should not be dismissed on the basis of non-significant statistical associations alone.  
 
It is interesting to note that both PolyPhen-2 and SIFT predicted the G1145S variant to be 
benign/tolerated. Some methods of analysis rely on weighted values being applied to rare variants 
based on these computational predictions (Price et al. 2010). The results of my in vitro studies 
demonstrate how the predictive functions of such algorithms should be taken as a guide only, and 
where possible, should not be relied upon instead of laboratory tests. Relying heavily on 
computational predictions in analyses may result in the effects of rare variants being 
underestimated.  
 
In addition to mechanistic similarities between the novel rare variants and R77H, we also see a 
similar magnitude of functional effect between R77H and one rare variant, G1145S. This raises an 
important point about the rare variant paradigm, which is often represented as a negative 
correlation between allele frequencies and disease risk (Bodmer and Bonilla 2008). Our in vitro 
models suggests a comparable functional effect, despite the large difference in the minor allele 
frequencies of these two missense variants in SLE cohorts; R77H (MAF =0.2) and G1145S (MAF 
≤0.0005). Furthermore, F941V has a comparable MAF (≤0.0002) to that of G1145S, yet has a 
significantly greater impact on phagocytosis. Despite defective phagocytosis being a robust 
paradigm in SLE biology, it is, of course, not the only mechanism by which impaired CR3 function 
predisposes to SLE risk. It is possible, then, that F941V and/or G1145S have variable effect sizes on 
other CR3 functions, such as the inhibition of Toll 7/8-induced pro-inflammatory cytokines; however, 
in the absence of ex vivo cells from multiple healthy individuals carrying these mutations, or 
additional suitable in vitro assays, we lack a sufficient model for this (C. Han et al. 2010; Rhodes et al. 
2012). In this instance, I recognise that it is difficult to estimate the contribution of these rare 
90 
 
variants to SLE risk. However, given their impact on phagocytosis – being equal to, or greater than, 
that of R77H – I feel it is sufficient to conclude their contribution cannot be dismissed.  
 
My work also expands on the specific understanding of the role of common ITGAM variants in SLE 
pathogenesis, particularly by resolving the uncertainty in the genetic literature concerning the 
possible additional functional effect of ITGAM SNP rs1143683 (A858V). SNP rs1143683 (A858V) and 
rs1143679 (R77H) are in relatively high LD (r2=0.55) in European populations and rs1143683 has 
been suggested as a secondary independent association signal within ITGAM in a Thai population 
(W. Yang et al. 2009). I wished to clarify this issue by including the A858V polymorphism in the in 
vitro model, along with another polymorphism rs11861251 (M441T), which is not a part of the same 
disease-associated haplotype (r2=0.017), which I envisaged as a negative control. Neither the A858V 
nor the M441T polymorphisms affected the CR3-mediated phagocytosis of iC3b-coated targets.  
 
Since my work was carried out, a publication has demonstrated the functional impact of the ITGAM 
polymorphisms rs1143683 and rs1143678, encoding A858V and P1146S present in the calf region 
and cytoplasmic tail of CD11b, respectively, on ex vivo neutrophils, independent of R77H (Y. Zhou et 
al. 2013). There is perfect LD between rs1143683 (A858V) and rs1143678 (P1146S) and for this 
reason the functional impact of these variants could not be analysed separately. Even though they 
report a significant reduction in the phagocytic capabilities of neutrophils from individuals with the 
858V/1146S variants, they hypothesise that the affect is attributable to the less conservative P1146S 
amino acid change (Y. Zhou et al. 2013). My results support this hypothesis of the functional 
neutrality of A858V. Of particular interest, patient 50:2.2, who harbours the G1145S rare variant, is 
also heterozygous for the P1146S polymorphism (Figure 4.1b). Through using the Integrative 
Genomics Viewer (IGV) programme to view aligned 454 sequencing reads (work carried out by Dr 
Ellen Thomas) we can see that the G1145S rare variant and P1146S polymorphism are in phase on 
the chromosome. G1145S had the least severe impact on phagocytic function (26% reduction); 
however, a functional alteration to two sequential amino acids could indeed have an impact greater 
than the additive effect of the G1145S and P1146S variants considered independently. This patient is 
also heterozygous for the associated R77H polymorphism (of note, the patient with F941V is 
homozygous WT for this variant). Heterozygosity of the SLE-associated R77H variant has been shown 
to be sufficient to significantly impair phagocytosis of iC3b-targets, including opsonised mouse 
apoptotic thymocytes, by ex vivo neutrophils, monocytes, and macrophages (Fossati-Jimack et al. 
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2013). This study argued that, as the heterozygous genotype is far more common in SLE populations 
(~20%) than 77H homozygosity (~3%), comparisons between WT with R77H heterozygous samples 
were more informative (Fossati-Jimack et al. 2013). It is likely, then, that the CR3 functions of patient 
50:2.2 are severely affected in vivo by the combination of these ITGAM variants (discussed further in 
7.2.1).  
 
The functional results of the COS-7 model used in this work emphasises that impaired phagocytosis 
of iC3b opsonised particles, a consequence of defective ‘outside-in’ signalling is one, but clearly not 
necessarily the only, functional mechanism underlying the association between specific ITGAM risk 
variants and SLE. It is notable that all three functional variants, R77H, F941V and G1145S, are located 
in different domains of the CD11b polypeptide (Figure 4.2) but have similar effects on signalling. 
None appear to directly influence known ligand binding sites (Diamond et al. 1993), but clearly 
specific amino acids throughout CD11b, from the N-terminal β-propeller (R77) domain through to 
the C-terminal cytoplasmic tail (G1145) are important in mediating CR3 ‘outside-in’ signals to the 
cytoplasm. 
 
The ‘hypothesis-free’ GWAS methodology has proven successful in highlighting novel disease-
associated polymorphisms for further functional analysis, but lacks statistical power to prove the 
association of most rare variants with disease. Recent approaches have identified rare variants in 
disease-associated loci very successfully, but estimating their contribution to disease risk has proven 
difficult. Conclusions are leading towards the notion that rare variants contribute little towards 
genetic variance (Hunt et al. 2013). My work demonstrates that once the functional consequence of 
a common variant has been clearly elucidated, this knowledge can be reapplied to provide proof of a 
role for additional candidate rare variants at the same locus. In a relatively small resequencing 
project, two functional deleterious rare variants at the ITGAM locus have been identified. This 
suggests that further screening of ITGAM for rare variants in a larger cohort of SLE cases promises to 
be worthwhile. If an association-based approach alone had been applied in this study, together with 
computational predictions, there would be no evidence of any potential contribution of these rare 
variants to SLE pathogenesis. However, it is not possible to disregard these variants given their 
genetic location, conservation, and deleterious effects on receptor function. If each of the 52 known 
SLE susceptibility loci contains a similar high number of modest effect-size rare variants then their 
contribution to the overall genetic component of disease susceptibility will be not inconsiderable. 
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However, perhaps we currently lack the correct tools for estimating the contribution of rare 























In addition to aiding our understanding of complex pathologies of disease, genetic studies may also 
provide avenues of directed therapies. Such an example may be true of the ITGAM association; a 
high-throughput screening cell-adhesion assay identified a novel agonist of CR3 which has anti-
inflammatory properties (Maiguel et al. 2011; Faridi et al. 2009).  
 
K562 cells stably transfected with CD11b/CD18, which show very little binding to the CR3 natural 
ligand fibrinogen prior to transfection, were used to identify small molecules that increased CR3-
mediated adhesion. Leukadherin-1 (LA1) is a small-molecule agonist that binds specifically to the αA-
domain of CD11b, causing allosteric activation of CR3 (Faridi et al. 2009). LA1 has been shown to 
increase the receptor’s affinity for multiple natural ligands in transfected cells and ex vivo human 
neutrophils, demonstrating that its effects are neither ligand- nor cell-specific (Maiguel et al. 2011). 
Furthermore, by increasing the CR3-mediated adhesion of neutrophils, LA1 decreases cell migration 
of both ex vivo and in vivo murine cells, suggesting a potential pharmacological use in inflammatory 
and autoimmune diseases (Maiguel et al. 2011). In contrast to anti-CD11b activating antibodies, 
which induce receptor clustering and global CR3 conformational changes, LA1 does not mimic 
natural ligands. This is thought to provide its therapeutic advantage over activating antibodies (Faridi 
et al. 2013). Given the demonstrated involvement of CR3 under-functioning in SLE susceptibility 
(Rhodes et al. 2012; MacPherson et al. 2011; Fossati-Jimack et al. 2013; Maiti et al. 2014), LA1 is a 
promising avenue for molecular-targeted SLE treatment. Particularly as LA1 stimulated phagocytosis 
of iC3b-coated sheep red blood cells by CD11b/CD18 transfected K562 cells (Maiguel et al. 2011). 
Furthermore, sub-phenotype analyses suggest the R77H variant is most strongly associated with 
renal manifestations of SLE (W. Yang et al. 2009; Kim-Howard et al. 2010), and, of particular interest, 
LA1 was shown to preserve kidney functions in a murine model of nephritis (Maiguel et al. 2011). 
 
The conclusions of one study, however, suggested a limitation for the potential therapeutic use of 
LA1 for SLE. Reed and co-workers demonstrated that LA1 pre-treatment of THP-1 cells and ex vivo 
macrophages from healthy human donors significantly reduced the TLR7/8-mediated secretion of 
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TNF by degrading the adaptor protein MyD88 (Reed et al. 2013). However, despite very modest 
numbers (n=3), this study concluded that R77H-heterozygosity was sufficient to diminish the LA1 
effect in ex vivo macrophages (Reed et al. 2013). The MAF of rs1143679 is estimated to be ≈0.15-0.2 
in SLE cases across multiple ethnicities (S. Han et al. 2009), and a genotypic restriction on the 
efficiency of LA1 would indeed be a caveat for its use as an SLE therapeutic.  
 
As discussed in section 1.4.4, there is growing evidence that CR3 acts as a regulator of immune cell 
signalling (C. Han et al. 2010; Bai et al. 2012). NK cells, in particular the CD56bright subset, are 
prominent producers of cytokines, yet the role of CR3 on NK cells has yet to be fully explored. It is 
possible, then, that LA1 could have similar CR3-dependent inhibitory effects on NK cells. Work 
carried out by Ben Rhodes (King’s College London) using ex vivo human NK cells from healthy 
volunteers either homozygous WT (R77) or homozygous risk (77H) demonstrated that pre-treatment 
with LA1 prior to 24 hour incubation with paired monocyte-derived cytokines (monokines) - IL-12 
and IL-15, or IL-12 and IL-18 - significantly reduced the secretion of pro-inflammatory cytokines IFN-γ 
and TNF, and the chemokine MIP-1β, compared with the vector control (DMSO), as measured by 
Cytometric Bead Arrays. No difference was observed in IL-8 secretion under either stimulation 
conditions, indicating an element of specificity to these inhibitory effects (Figure 5.1; manuscript 
under review). Even though the SLE-associated R77H polymorphism has been shown to affect CR3 
function following natural ligand engagement (MacPherson et al. 2011), including its regulatory 
functions (Rhodes et al. 2012), the R77H variant had no effect on the LA1-mediated inhibition of NK 
cell cytokine production following monokine stimulation. This result contradicts that of Reed and 
colleagues discussed above (Reed et al. 2013). However, the study by Ben Rhodes is better able to 
detect a genotypic effect, firstly due to a much greater sample size (n>20), and secondly due to the 
use of opposing genotypic groups (R77 v 77H). 
 
In order to understand the mechanism through which CR3 engagement with LA1 down-regulated 
cytokine secretion in NK cells, as demonstrated by Ben Rhodes (Figure 5.1), I employed an 
intracellular FACS assay with phospho-specific antibodies (Methods 2.9). I measured the effects of 
LA1 pre-treatment on the tyrosine phosphorylation of signal transducers and activators of 
transcription (STAT) and p38 MAPK in NK cells following stimulation with the paired monokines; IL-




Figure 5.1 LA1 significantly reduces the production of pro-inflammatory cytokines by NK cells  
NK cell pre-treatment with LA1 before IL-12 and IL-15 (n=20; top panel), or IL-12 and IL-18 (n=28; 
bottom panel) stimulation significantly reduced production of cytokines IFN-γ, TNF, and MIP-1β, but 
not IL-8. Healthy volunteers were either homozygous WT or homozygous risk for the SLE-associated 
R77H polymorphism. No genotypic effect was observed.  
This work was carried out and these data were provided by Ben Rhodes. The remainder of the data 



































































































































P<0.0001 P=0.0008 P<0.0001 P=0.50













5.2.1 LA1 does not reduce cell viability in NK cell populations of high purity 
 
I used a negative selection kit to isolate NK cells from whole blood of healthy donors and tested the 
purity of the cell population using the following cell surface marker antibody panel: anti-CD56 (APC), 
anti-CD16 (FITC), anti-CD14 (PerCP-Cy5.5), anti-CD3 (Pacific Blue), and anti-CD19 (PE) (Methods 2.9). 
I consistently observed a high degree of purity, as represented in Figure 5.2. Donors were not 
selected by R77H genotype because there did not appear to be a genotypic difference in the 
cytokine secretion assays. 
 
Using a CellTiter-Glo® Luminescent Cell Viability Assay (Methods 2.9.3), I did not observe a 
significant difference in cell viability of 50,000 NK cells (0.5x106/ml) following 24 hour incubation 
with DMSO (vector control) or LA1, either alone or in combination with paired monokines IL-12 and 
IL-15, or IL-12 and IL-18 (Figure 5.3). Although all conditions resulted in a slight decrease in cell 
viability when compared with NK cells incubated without any stimulation, it is the comparison of LA1 
against its vector control that is of importance for the experiments described here. Therefore, the 
LA1-mediated reduction in NK cell cytokine production, as observed by Dr Ben Rhodes (Figure 5.1) 
cannot be attributed to reduced cell viability. This is in concordance with a previous study on the  in 
vivo effects of LA1 in mice (Maiguel et al. 2011). 
 
In further Phosflow experiments, NK cells were in fact used at a higher concentration of 1x106/ml, 
yet LA1 was used at the same concentration (1:2000).  Therefore, the cell viability results presented 
here demonstrate that LA1 is not toxic to NK cells even when the receptor: ligand ratio is double that 








Figure 5.2 Isolation of NK cells from PBMCs by negative selection yields cell population with high 
purity Following negative selection from PBMCs, 2x105 cells were stained with anti-CD56 (APC), anti-
CD16 (FITC), anti-CD14 (PerCP-Cy5.5), anti-CD3 (Pacific Blue), and anti-CD19 (PE). A) Scatter-plot of 
APC and FITC staining separates the CD56dimCD16+ (Q2) and CD56bright CD16- cells (Q1). An 
insignificant amount of B) CD3+ T cells (Q5), CD19+ B cells (Q7), and C) CD14+ monocytes (Q10) were 









Figure 5.3 LA1 does not reduce NK cell viability The addition of DMSO or LA1, alone or in 
combination with paired cytokines (IL-12 and IL-15, or IL-12 and IL-18) slightly decreased NK cell 
viability compared with no stimulation. However, no significant difference in NK cell viability was 















































































5.2.2 Measuring STAT phosphorylation in NK cells 
 
I surveyed the effects of LA1 on NK cells stimulated with IL-12 and IL-15, or IL-12 and IL-18, by 
measuring the phosphorylation of three STAT proteins - STAT3, STAT4, and STAT5 - known to be of 
particular importance in IL-12, IL-15 and IL-18 signalling and NK cell production of IFN-γ, TNF, and 
MIP-1β, as demonstrated in Figure 5.4 (Nakahira et al. 2001; Carroll, Paunovic, and Gadina 2008; 







Figure 5.4 Cartoon representation of the specificity of STAT and MAPK signalling in, and cytokine 
and chemokines production by, NK cells following activation with IL-12, IL-15, and IL-18. 
IL-15R and IL-12R engagement activates JAKs, which in turn phosphorylate the cytokine receptors, 
allowing the phosphorylation of specific STATs. Phosphorylated STATs can dimerise, enabling their 
translocation to the nucleus and subsequent activation of transcription. IL-15 signalling activates 
STAT3 and STAT5, which are able to form hetero/homodimers. IL-12R signalling is STAT4-dependent. 
Furthermore, this signalling cascade can induce IL-18Rβ expression. The IL-18Rα chain 
phosphorylates p38 MAPK; the IL-18Rβ chain, when expressed, ultimately signals through NFκB. The 
signalling molecules presented in bold were measured with phosphor-specific antibodies. The 
cytokine and chemokines milieu shown here are those measured in Figure 5.1, and those presented 





























As the cytokine data was measured after 24 hour incubation (Figure 5.1) and the mechanism of LA1-
mediated cytokine/chemokine regulation is incompletely understood, I measured the 
phosphorylation of STAT3, STAT4, and STAT5 at a short time point (10 minutes) and an extended 
time-point (2 hours). Negative regulation of the JAK-STAT pathway occurs through multiple 
mechanisms, such as dephosphorylation (e.g. through tyrosine phosphatases deactivation of JAKs) or 
degradation of activated JAKs/STATs (e.g. as seen with suppressors of cytokine signalling (SOCS)). By 
taking early and late time-point measurements, I hoped to be able to test whether LA1 decreased 
the rate of phosphorylation or increased the rate of dephosphorylation. 
 
For each individual volunteer, NK cells with DMSO and LA1 pre-treatment, but no cytokine 
stimulation (T=0), were used to calculate the fold-change of median fluorescence intensity at the 
indicated time points (Figure 5.5). I also used a Pacific Blue-conjugated anti-CD56 antibody to enable 
the delineation of the CD56bright NK cell population during FlowJo analysis (Methods 2.9.7).  
 
Figure 5.5 Fold-change of STAT5 phosphorylation as observed using phospho-specific antibodies  
Median fluorescent intensity (MFI) values were measured prior to monokine stimulation (red 
histogram) and at specific time-points following monokine stimulation (blue histogram). Fold-
changes in STAT phosphorylation were calculated by dividing MFI following stimulation by the basal 
MFI (Methods 2.9.8). Representative data from one experiment shows fluorescence of APC-




5.2.3 The effects of LA1 on STAT phosphorylation following IL-12 and IL-15 stimulation  
 
I observed a large fold-change increase in STAT5 phosphorylation, in both total and CD56bright NK cell 
populations, after 10 minutes stimulation with IL-12 and IL-15. STAT5 is known to be a key mediator 
of IL-15 signalling in NK cells (Johnston et al. 1995; Strengell et al. 2003). Furthermore, pre-treatment 
with LA1 significantly reduced this fold-change in both total (p=0.02) and CD56bright (p=0.004) NK cell 
populations (Willcoxon’s matched paired test; Figure 5.6a). STAT5 phosphorylation was still elevated 
at similar levels after 2 hours, but the LA1 effect was no longer significant (Figure 5.6a).  
 
An increase in STAT4 phosphorylation was also seen following IL-12 and IL-15 stimulation, although 
the rate of this increase was much slower; the fold-change observed after 2 hours incubation with 
the paired monokines was much greater than that observed after 10 minutes (Figure 5.6b). LA1 did 
not appear to affect the phosphorylation of STAT4 (Figure 5.6b). A very modest fold-change in STAT3 
phosphorylation was seen at both time points and, once again, LA1 did not appear to affect this 
(Figure 5.6c). 
 
5.2.4 LA1 delays the IL-15-mediated phosphorylation of STAT5 
 
STAT phosphorylation is very proximal in cell signalling cascades, and, given the LA1-mediated 
reduction in pSTAT5 after 10 minutes incubation with IL-12 and IL-15, this suggested that LA1 is 
reducing the rate of phosphorylation, as opposed to triggering a negative feedback loop. 
 
I used scatter plots with anti-pSTAT5 (APC) on the x-axis and anti-CD56 (Pacific Blue) on the y-axis, as 
shown in Figure 5.7a, to compare the shift in pSTAT5 positivity. The y-axis gate is set to distinguish 
CD56dim and CD56bright populations; pSTAT5 positivity was set at >103 log-APC. Using this gating 
strategy, I compared the shift in percentage pSTAT5 positivity across nine independent experiments. 
Pre-treatment with LA1 significantly lowered the percentage of pSTAT5 positive cells (Q8; Figure 
5.7a) at 10 minutes, in both CD56dim (p=0.03) and CD56bright (p=0.004) cells (Willcoxon’s matched 
paired test; Figure 5.7b). 
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Figure 5.6 The effect of LA1 on STAT phosphorylation in IL-12 and IL-15 activated NK cells  
LA1 pre-treatment significantly decreases the fold-change in pSTAT5 (A), but not pSTAT4 (B) or 
























































































































































































































































































































































































































Figure 5.7 Reduced pSTAT5 positive cell population following LA1 pre-treatment 
A) Scatter-plots show pSTAT5 (x-axis) and CD56 (y-axis) staining, before (left panel) and after (right 
panel) 10 minutes incubation with IL-12 and IL-15. Representative data from one experiment shows 
the effects of DMSO (top panel) and LA1 (bottom panel) pre-treatment. B) Comparison of 







5.2.5 The effects of LA1 on STAT phosphorylation following IL-12 and IL-18 stimulation  
 
IL-12-mediated STAT4 tyrosine phosphorylation is critical to induce IL-18Rβ expression (Kunikata et 
al. 1998; Nakahira et al. 2001; Sareneva, Julkunen, and Matikainen 2000). This is paramount for IL-18 
signal transduction, as the IL-18Rα chain alone binds IL-18 but does not induce a pro-inflammatory 
signalling cascade (Nold-Petry et al. 2009; Hyun Kim et al. 2001; Wu et al. 2003). Measuring STAT4 
tyrosine phosphorylation in this instance was therefore fulfilling two functions: directly measuring 
the effects of LA1 on IL-12R signalling, and indirectly measuring the potential affect of LA1 on IL-
18Rβ expression (Nakahira et al. 2001). 
 
An increase in pSTAT4 was observed following incubation with IL-12 and IL-18, and the fold-change 
was much greater after 2 hours incubation compared with that after 10 minutes (Figure 5.8b). The 
fold-change in pSTAT4 observed under both IL-12 and IL-15, and IL-12 and IL-18 activation are 
similar, suggesting that phosphorylation of STAT4 is mainly a result of IL-12 signalling, as previously 
reported (Matikainen et al. 2001). However, LA1 pre-treatment did not affect STAT4 
phosphorylation (Figure 5.8b). 
 
As expected, no increase in pSTAT5 was seen at either time point after IL-12 and IL-18 stimulation 












Figure 5.8 Fold-changes of pSTATs in NK cells activated with IL-12 and IL-18 
LA1 pre-treatment does not affect the fold-change in pSTAT5 (A), pSTAT4 (B) or pSTAT3 (C), at either 



















































































































































































































































































































































































































5.2.6 The effect of LA1 pre-treatment on the time-course of STAT phosphorylation 
 
The contrast between the kinetics of STAT4 and STAT5 phosphorylation observed across two time-
points – the former exhibiting a slower rate of phosphorylation, and the latter showing rapid yet 
sustained phosphorylation (Figures 5.5 and 5.7) – suggested that the time-courses of 
phosphorylation for the three STAT molecules may be of interest. I therefore wished to expand the 
range of time points to construct time-courses of phosphorylation.  
 
Under the same experimental conditions, and in addition to 10 minutes and 2 hours, I measured the 
fold-change in median fluorescence intensity at 5, 30, and 60 minutes. In some instances, 
measurements were also taken after three and four hours of monokine activation (Figure 5.9 and 
Figure 5.10). These experiments were limited by the number of NK cells obtained from each donor 
sample, therefore I was unable to measure all STATs across every time point. 
 
LA1 pre-treatment reduced the fold-change in pSTAT5 across all time points in both total and 
CD56bright NK cells following IL-12 and IL-15 activation (Figure 5.9a), adding further evidence that 
inhibition of IL-15-mediated STAT5 tyrosine phosphorylation is a possible mechanism through which 
LA1 inhibits NK cell cytokine production (Figure 5.1). Interestingly, despite IL-12 and IL-18 activation 
appearing not to induce an increase in pSTAT5 in the initial study with T=10 minutes and T=2 hours, 
a two-fold increase in the CD56bright subset was observed after 60 minutes incubation with the paired 
monokines (Figure 5.10a). However, unlike the down-regulation observed under the IL-15 activation, 
pre-treatment with LA1 did not affect the fold-change of pSTAT5 in this instance. 
 
Overall, the combination of IL-12 and IL-15 increased the fold-change in pSTAT4 (Figure 5.9b) more 
so than that of IL-12 and IL-18 (Figure 5.10b). Even though STAT4 is known to be a key signalling 
molecule for IL-12-mediated signalling, IL-15 has also been shown to signal through STAT4 tyrosine 
phosphorylation (Strengell et al. 2003). My data suggest that IL-12 and IL-15 synergistically induce a 
greater degree of STAT4 tyrosine phosphorylation.  
 
A modest increase in pSTAT3, with the greatest level of phosphorylation seen at 30 and 60 minutes, 
was observed following IL-12 and IL-15 stimulation (Figure 5.9c). Once more, due to the number of 
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NK cells obtained from whole blood being the limiting factor in these experiments, there is a great 
deal of variability in pSTAT3 fold-change under the IL-12 and IL-15 activated cells, and I feel further 
experiments are needed to confirm there is indeed no LA1 effect on STAT3 tyrosine phosphorylation. 
Very little change in pSTAT3 was observed following IL-12 and IL-18 stimulation. Although the fold-
change was slightly higher in LA1 treated cells, the fold-change was very modest and therefore 
unlikely to be indicative of a functional difference (Figure 5.10c).  
 
Under both activating conditions, the CD56bright NK cells consistently showed a greater degree of 
STAT tyrosine phosphorylation. This observation is in concordance with the paradigm that CD56bright 



















Figure 5.9 Time course of STAT tyrosine phosphorylation following IL-12 and IL-15 activation 
The effects of DMSO (black) and LA1 (red) pre-treatment on (A) pSTAT5, (B) pSTAT4, and (C) pSTAT3 
fold-change in total (left panel) and CD56bright (right) NK cell activated with IL-12 and IL-15. 
Total NK















































































































































































Figure 5.10 Time course of STAT tyrosine phosphorylation following IL-12 and IL-18 activation 
The effects of DMSO (black) and LA1 (red) pre-treatment on (A) pSTAT5, (B) pSTAT4, and (C) pSTAT3 
fold-change in total (left panel) and CD56bright (right) NK cells activated with IL-12 and IL-18. 
Total NK



































































































































































5.2.7 LA1 does not affect p38 MAPK phosphorylation in IL-12 and IL-18 activated NK cells 
 
The two receptor chains that form the IL-18 receptor complex – IL-18α and IL-18Rβ – have different 
functions and utilise different signalling pathways. The former, which binds IL-18, utilises the MAP 
kinases and, through inhibition of its expression, has been shown to harbour inhibitory functions 
(Nold-Petry et al. 2009; Carroll, Paunovic, and Gadina 2008); the latter recruits MyD88 and is 
essential for IL-18R pro-inflammatory signalling (Adachi et al. 1998; Suzuki et al. 2003). I saw very 
modest changes in phospho-p38 following IL-12 and IL-18 activation, and LA1 did not appear to 
affect this (Figure 5.11). As described above, my STAT4 data did not suggest dysregulation of IL-18Rβ 
expression was a potential mechanism for LA1-mediated effects on IL-18 signalling. Therefore, it is 
very possible that LA1 affects IL-18Rβ signalling; a potential area for future work. 
 
 
Figure 5.11 Time course of p38 MAPK phosphorylation following IL-12 and IL-18 activation 
The effects of DMSO (black) and LA1 (red) pre-treatment on the fold-change of phosphor-p38 MAPK 
in total (left panel) and CD56bright (right) NK cell activated with IL-12 and IL-18. 
Total NK


























































In this chapter I have demonstrated that LA1 significantly reduces the IL-15-mediated fold-change in 
STAT5 tyrosine phosphorylation, in both total NK cells and the CD56bright subset, through a 
mechanism of decreasing the rate of phosphorylation.  Synergistic activation of NK cells with paired 
monocyte-derived cytokines has been shown to produce a milieu of pro-inflammatory cytokines and 
chemokines (Fehniger et al. 1999). Even though stimulation with individual cytokines has been 
shown to result in relatively modest quantities of secreted products, IL-15 alone stimulates NK cells 
to produce large quantities of MIP-1β and TNF (Fehniger et al. 1999). Also, IL-15 alone has been 
shown to activate IFNG gene expression and IFN-γ protein production (Strengell et al. 2003). 
Therefore, it is possible that the reduced fold-change in STAT5 tyrosine phosphorylation presented 
in this chapter at least partly explain the reduced production of IFN-γ, TNF, and MIP-1β by IL-12 and 
IL-15 activated NK cells (Figure 5.11). 
 
Furthermore, the data presented here suggest that LA1-mediated CR3 signalling interferes with the 
events that take place upstream of or during STAT5 phosphorylation: the activation of JAK kinases on 
the IL-15 receptor chains, the subsequent recruitment or binding of STAT5 to the phosphorylated 
receptor chains, or the phosphorylation of STAT5. Specifically, activation of JAK1 and JAK3 associated 
with the IL-2Rβ and γc-chains, respectively, have been shown to be crucial for STAT5 tyrosine 
phosphorylation in response to IL-15 (Johnston et al. 1995; Carroll, Paunovic, and Gadina 2008). It is 
possible, then, that LA1 has JAK kinase specificity, in which case other JAK1- and JAK3-dependent 
cytokine signalling pathways may also be affected (Jian-Xin Lin, Judy Mietz 1996).  
 
A CR3-mediated effect on JAK kinases has recently been shown in human monocytes/macrophages. 
IL-13-mediated up-regulation of CD36 expression on activated human monocytes/macrophages is 
inhibited by pre-ligation of CR3 with either anti-CD18 or anti-CD11b antibodies (Yakubenko et al. 
2013). CR3 activation blocks the phosphorylation of IL-13 receptor-associated Jak-2 and Tyk-2 
kinases, which further inhibits the downstream tyrosine and serine phosphorylation of STAT1, 
STAT3, and STAT6 (Yakubenko et al. 2013). These effects were dependent on CR3 ligation occurring 
before cellular activation. Interestingly, this demonstrated agonist chronology is also paramount for 
the LA1-mediated effects on TLR signalling; TLR activation before CR3 ligation with LA1 overrides its 
regulatory effects (Reed et al. 2013). 
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On the other hand, interleukins can activate common JAKs yet their downstream signalling can 
diverge at the STAT level; it is the tyrosine-based motifs in the receptor components that dictate 
their STAT specificity (Stahl et al. 1995; Johnston et al. 1995). For instance, IL-12 and IL-13 both 
utilise Jak-2 and Tyk-2, yet IL-13, unlike IL-12, does not phosphorylate STAT4 (Yakubenko et al. 2013). 
In this chapter I have shown the effects of LA1 on IL-15R signalling; therefore LA1-mediated effects 
could be specific for IL-2Rβ or the common γc-chain. For example, if the observed effects were a 
product of common γc-chain-specificity, LA1 could plausibly regulate the signalling of all other IL-2-
family cytokine receptors which contain the γc-chain: IL-2, IL-4, IL-9, and IL-21 (Lin and Leonard 
2000). Particularly as all common γc-chain-containing receptors have been shown to signal through 
STAT5 (Lischke 1998). The IL-2Rβ, on the other hand, is only shared by IL-2 and IL-15 receptor 
complexes (Lin and Leonard 2000). Therefore, measuring the effects of LA1 on the NK cell activating 
effects of other cytokines may help delineate the molecular mechanisms of LA1-mediated NK cell 
regulation and determine the level at which its specificity lies: cytokine receptor, JAK, or STAT. 
 
An unexpected observation was that of a short-lived, two-fold increase in STAT5 phosphorylation in 
CD56bright cells after 60 minutes incubation with IL-12 and IL-18 (Figure 5.10a). The demonstration 
that LA1 pre-treatment did not affect this suggests that its effects are not STAT5-specific. However, 
the involvement of STAT5 in IL-12 or IL-18 signalling has not been previously described; therefore 
any further interpretation of this observation is very difficult. 
 
The epitope of the anti-pSTAT5 antibody used in this study identifies the phosphorylated tyrosine at 
amino acid 694 (Y694) of STAT5A. However, the orthologous phosphorylation site in STAT5B is Y699, 
and by comparing the flanking amino acid sequences of these tyrosine residues, we can see that the 
antibody is not predicted to differentiate between the STAT5A and STAT5B isoforms (Table 5.1). If I 
had the ability to measure both STAT5 isoforms independently, it is possible that I would see a fold-
change difference in only one isoform. Therefore, the reduction presented in this chapter could 
indeed be a modest estimation of the true effects of LA1 on STAT5 signalling. That is, if only one of 
STAT5A or STAT5B tyrosine phosphorylation is inhibited by LA1, the results obtained by the anti-
pSTAT5 antibody may be diluted. It may be possible to estimate STAT5 isoform specificity by using a 
qPCR with STAT5A and STAT5B specific targets to delineate which, if not both, STAT5 isoform is 
regulated by CR3 (Basham et al. 2008). 
113 
 
Table 5.1 Comparison of STAT5A and STAT5B peptide sequences surrounding the anti-pSTAT5 
antibody epitope pY694 
The amino acid sequence surrounding the Y694 (bold) of STAT5A is identical to the orthologous 
amino acid sequence in STAT5B (Y699). Therefore the anti-pSTAT5 antibody will recognise both 
isoforms when they are phosphorylated. 





In addition to forming homodimers, under certain conditions, which are incompletely understood, 
STATs can form heterodimers, and STAT5 has been shown to heterodimerise with STAT3. Indeed, 
the ability to induce homo- or heterodimers may be indicative of yet another level on which 
signalling specificity is controlled by cytokine receptors (Delgoffe and Vignali 2013). Furthermore, 
STAT3 and STAT5 have been shown to reciprocally regulate IL-17 production (X. Yang et al. 2011). 
The LA1-mediated effects on pSTAT5 presented here may therefore indirectly affect STAT3; either by 
skewing the cellular ratio of pSTAT5:pSTAT3, or by reducing the possibility of pSTAT3-pSTAT5 
heterodimer formation.  
 
IL-18 binds the IL-18Rα chain, but, in the absence of IL-18Rβ expression, no pro-inflammatory signal 
is induced (Suzuki et al. 2003; Adachi et al. 1998; Hyun Kim et al. 2001; Wu et al. 2003). Absence or 
inhibition of IL-18Rα leads to the somewhat paradoxical increase in MAP kinase signalling and 
cytokine production, due to the anti-inflammatory properties of IL-18Rα (Nold-Petry et al. 2009; 
Lewis and Dinarello 2006). I saw a short-lived, modest increase in phosphorylated p38 MAPK, but no 
evidence that LA1 affected this. 
 
IL-15 and IL-12 have been shown to induce IL-18Rβ expression (Hyun Kim et al. 2001; Kunikata et al. 
1998; Nakahira et al. 2001). For this reason, without IL-12 or IL-15 co-stimulation, IL-18 does not 
induce IFN-y (Kunikata et al. 1998). STAT4 signalling is paramount to the IL-12-mediated induction of 
IL-18Rβ expression (Sareneva, Julkunen, and Matikainen 2000; Nakahira et al. 2001). Therefore, the 
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observation that LA1 pre-treatment did not affect STAT4 tyrosine phosphorylation suggests 
dysregulation of IL-12-mediated IL-18Rβ expression is not a likely mechanism of LA1 function. 
However, it would be of interest to confirm this by measuring the cell surface expression of IL-18Rβ 
following IL-12 activation, with and without LA1 pre-treatment. 
 
It was not possible to include members of the IL-18Rβ signalling cascade in my flow cytometry 
experiment, due to the lack of phospho-specific antibodies. IL-18Rβ recruits MyD88, which in turn 
phosphorylates IRAK1 and IRAK4, ultimately leading to NFκB translocation (Strengell et al. 2003; 
Carroll, Paunovic, and Gadina 2008; Kanakaraj et al. 1999). It is likely, then, that LA1 may interfere 
with the IL-18Rβ signalling cascade, and it is of particular interest that the LA1-mediated inhibition of 
TLR-signalling in monocytes/macrophages is thought to be MyD88-dependent  (C. Han et al. 2010; 
Reed et al. 2013). 
 
CR3 engagement has been shown to have regulatory effects in cell types including monocytes, 
macrophages, and dendritic cells (Rhodes et al. 2012; C. Han et al. 2010; Bai et al. 2012). 
Furthermore, the SLE-associated R77H variant has been shown to negatively affect these regulatory 
functions. Using the U937 monocyte cell line, Macpherson and colleagues demonstrated elevated 
levels of IL-6 production in CD11b-77H-expressing cells compared with CD11b-WT (MacPherson et 
al. 2011). Additionally, pre-treatment of ex vivo monocytes with iC3b-coated RBCs prior to TLR7/8 
engagement with the R848 agonist results in reduced secretion of pro-inflammatory cytokines IL-1β, 
IL-6 and TNFα. However, this regulatory effect is significantly less pronounced in 77H-homozygous 
cells (Rhodes et al. 2012).  
 
It is possible that CR3 plays a similar regulatory role on NK cells. However, the role of CR3 on NK cells 
is incompletely understood and is often overlooked in reviews of the topic (Fagerholm et al. 2013). 
The combined work presented in this chapter is the first study of the effects of LA1 on NK cell 
function. The lack of a genotypic effect in the regulation of NK cell cytokine production 
demonstrates how LA1-mediated allosteric activation of CR3 is very different to that of natural 
ligands. Even though the effects of R77H on the functions of NK cells have not been addressed, this 
SLE-associated variant is likely to have functional consequences given the multitude of effects 
already demonstrated using various in vitro models and ex vivo cells (MacPherson et al. 2011; 
Rhodes et al. 2012; Fossati-Jimack et al. 2013). In addition, LA1 does not mimic natural ligands (Faridi 
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et al. 2013). Therefore, the results of this study are not a model for the role of CR3 on NK cells 
following natural ligand ligation and should not be extrapolated as such.  
 
There are reports in the literature of pro-inflammatory roles of CR3 (Fan and Edgington 1993). One 
study using human monocytes reported that ligation of CD11b with antibodies or soluble CD23 
induced the production of MIP-1α and MIP-1β (R. Rezzonico 2001). These data are very much in 
contrast with LA1-mediated effects presented here, which highlight the contrasting effects of CR3 
ligands. However, ligand avidity has been shown to dramatically influence CR3 signalling, which may 
explain these paradoxical results (Wang et al. 2010). 
 
Given the cellular distribution of CR3 expression, in an in vivo setting LA1 is likely to have very 
significant systemic regulatory effects. CR3 ligation with anti-CD11b antibodies or iC3b suppresses IL-
12 production by bacteria-infected or IFN-γ-stimulated monocytes (Marth and Kelsall 1997; Yoshida 
et al. 1998), and a recent study shows that Leishmania major-mediated inhibition of IL-12 secretion 
by macrophages is CR3-dependent (Ricardo-Carter et al. 2013). Once more, the effects of specific 
CR3 ligands should not be used to predict the effects of other agonists, as stated above. However, if 
LA1 were also to suppress IL-12 production by monocytes, coupled with its demonstrated regulatory 
effects on monokine-stimulated NK cells, LA1 could lead to a significant systemic decrease in pro-
inflammatory cytokines.  
 
In summary, the work presented in this chapter demonstrates that LA1: 
 Inhibits the IL-15-mediated STAT5 tyrosine phosphorylation 
 Does not affect IL-12-mediated STAT4 tyrosine phosphorylation, and for this reason is 
unlikely to affect the IL-12-mediated induction of IL-18Rβ expression 
 Does not affect the p38 MAPK phosphorylation following IL-18 signalling.  
 
As described in this discussion, further experiments are of both great importance and interest to 
further our understanding of the regulatory effects of LA1. These experiments are summarised in 
Chapter 7.  
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Reduced copy number of FCGR3B on chromosome 1q23.3 is robustly associated with SLE 
(Pmeta=9.1x10
-7, OR=1.59; McKinney & Merriman, 2012), and has been shown to be strongly 
correlated with the CD16b protein expression and function (Morris et al. 2010; Willcocks et al. 2008). 
Within the same complex FCGR genomic locus, homozygosity of the minor allele of the rs1050501 
polymorphism (Chr1:161643798) located in exon 5 of FCGR2B and encoding a non-synonymous 
coding variant I232T within the transmembrane domain of inhibitory receptor CD32b, has also been 
shown to be associated with SLE (Pmeta=8 x10
-6, OR=1 .73; Willcocks et al., 2010). This polymorphism 
has been shown to reduce the inhibitory function of CD32b on B cells and macrophages (Xiaoli Li et 
al. 2003; Kono et al. 2005; Clatworthy et al. 2007). Studies in Southeast Asian cohorts have shown 
consistent associations between FCGR2B-232T homozygosity and SLE (Chen et al. 2006; Kyogoku et 
al. 2002; Siriboonrit et al. 2003; Chu et al. 2004), whereas studies in European cohorts have been 
inconsistent, with some, albeit small, studies failing to find a significant association (Xiaoli Li et al. 
2003; V. Magnusson 2004). It is possible that the lower minor allele (C) frequency in European 
populations (MAF=0.1) compared with that in Southeast Asians (MAF=0.22-0.25), resulting in 
reduced power to detect an association, explains these discrepancies (Clatworthy et al. 2007; Chen 
et al. 2006; Siriboonrit et al. 2003; Kyogoku et al. 2002; Chu et al. 2004). Nonetheless, the FCGR2B-
I232T effect has consistently been shown to be in the same direction and meta-analyses have 
successfully demonstrated a strong disease association with FCGR2B-232T homozygosity (Willcocks 
et al. 2010; Niederer et al. 2010b). 
 
The FCGR3B copy number variable region spans ~85Kb of the FCGR locus, and, in addition to the 
complete absence of the FCGR3B gene, a deletion also amalgamates the coding region of FCGR2B 
with the regulatory region of FCGR2C resulting in the ectopic expression of the inhibitory receptor 
CD32b on NK cells (Mueller et al. 2013), as discussed previously in section 1.7.4. 
 
In this study I wished to investigate whether the SLE-association with reduced FCGR3B copy number 
was partly explained by the ectopic expression of FCGR2B. I genotyped the FCGR2B-I232T 
polymorphism (rs1050501) and estimated FCGR3B copy number variation (CNV) in SLE cases and 
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healthy controls of European ancestry to test for a genetic interaction between the two SLE-
associated variations. If it is possible to identify epistasis between associated variants, we may find 
that we have explained far more disease heritability than previously thought (Zuk et al. 2012). 
 
6.2 Results 
6.2.1 Genotyping FCGR2B-I232T 
 
I used PCR amplification followed by capillary sequencing (Figure 6.1) to genotype the rs1050501 
SNP (FCGR2B-I232T) in 627 SLE cases and 864 controls (Methods 2.1.2). Due to the high sequence 
identity between the 5’ regions of FCGR2B and FCGR2C (see Introduction 1.7.1) it is paramount to 
design PCR primers that will provide FCGR2B specificity for accurate genotyping of the rs1050501 
polymorphism. I used primers as described previously (P. Zhou et al. 2008; Morris et al. 2010), 
whereby PCR specificity is achieved from the reverse primer, which anneals to intron 5 of the 
FCGR2B gene (chr1:161645840-161645862), downstream of the FCGR2B/C homologous region. 
 
I did not observe a deviation from Hardy-Weinberg equilibrium for the rs1050501 genotype 
frequencies within the control samples (χ2=0.71; p=0.4). Also, I observed a MAF of 0.10, which is 
consistent with a previous estimates in European cohorts (Clatworthy et al. 2007). Therefore I am 
confident in the accuracy of my genotype results (Table 6.1a).  
 
6.2.2 FCGR2B-I232T Case/Control Analysis 
 
I used chi-squared tests (2x2 contingency table; df =1) to compare allele frequencies of the 
rs1050501 variant between cases and controls, as summarised in Table 6.1c. I did not observe a 
significant difference at the 95% level using 627 SLE cases and 864 controls (χ2=0.8; p=0.37).  232T-
homozygosity has previously been associated with SLE (Kyogoku et al. 2002; Willcocks et al. 2010). I 
observed no evidence of an association between 232T-homozygosity (genotype = CC) and disease 
risk at the 95% level (Table 6.1b; p=0.17; Fisher’s exact test).  The genotype frequencies for the 
control group - 0.987 for TT and TC combined, and 0.013 for CC (232T-homozygous) - correlate very 
strongly with those reported by Willcocks and colleagues, in which the 1958 Birth Cohort was also 
used (Willcocks et al. 2010). This indicates a high degree of reproducibility in the genotyping of 
rs1050501. The low MAF (0.1) resulted in very small numbers for the homozygous risk group in both 
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cases and controls (Table 6.1a). However, the cohort size (n=1491) is comparable to a previous study 
which detected an association (n=1622; Willcocks et al., 2010), suggesting I had sufficient power. 
 
 
Figure 6.1 FCGR2B rs1050501 genotyping by capillary sequencing 
(A) An ethidium bromide-stained agarose gel as observed under UV-transillumination showing the 
3Kb amplified fragment of FCGR2B following Long-Range PCR amplification. The Hyper Ladder I DNA 
ladder (Lane 1) and PCR negative control (Lane 3) are shown. (B) Electropherogram representations 









Table 6.1 FCGR2B rs1050501 genotyping results for cases and controls.  
A) Absolute genotype counts and calculated frequencies are presented for 627 cases and 864 
controls. No deviation from Hardy-Weinberg was observed in controls (χ2=0.71; p=0.4). B) Combined 
genotype counts and frequencies of homozygous WT (TT) and heterozygous (TC) compared with 
homozygous risk (CC). No significant difference in 232T-homozygosity was observed (p=0.17; Fisher’s 
exact test). C) Absolute allele counts and calculated frequencies for 1254 SLE chromosomes and 





Cases (n=627) Controls (n=864) 
n Frequency n Frequency 
TT 516 0.823 701 0.811 
TC 108 0.172 152 0.176 





Cases (n=627) Controls (n=864) 
n Frequency n Frequency 
TT or TC 624 0.995 853 0.987 





Cases (n=1254) Controls (n=1728) 
n Frequency n Frequency 
T 1140 0.909 1554 0.899 















































6.2.3 Meta-analysis of FCGR2B association 
 
I conducted a meta-analysis by combining my data with that of five independent cohorts of 
European ancestry: Swedish (n=491; V. Magnusson 2004), European American (n=285; Li et al. 
2003), UK (n=1622; Willcocks et al. 2010), Swedish (n=544; Niederer et al. 2010b), and UK (n=650; 
Niederer et al. 2010b), as reported fully in the supplementary data of two publications (Niederer et 
al. 2010b; Willcocks et al. 2010). As stated above, my control cohort was partly made up by samples 
from the 1958 Birth Cohort, as was the UK cohort from the study by Willcocks and colleagues. 
Therefore, to avoid the potential of duplicate samples, I removed the data for the 494 samples from 
the 1958 Birth Cohort included in my genotyping, leaving 370 controls from the TwinsUK 
Bioresource cohort (Methods 2.1.2). This reduced my final sample size to 997.  
 
I combined the data, as summarised in Table 6.2, and performed a meta-analysis using a total of 
1830 cases and 2759 controls (n=4589; Figure 6.3). I found strong evidence for an association with 






Table 6.2 Summary data of the FCGR2B-232T homozygosity and SLE risk meta-analysis.  
The combined rs1050501 genotype data from six independent cohorts of European ancestry:  UK 
(n=997; this study), Swedish (n=491; V. Magnusson 2004), European American (n=285; Li et al. 2003), 
UK (n=1622; Willcocks et al. 2010), Swedish (n=544; Niederer et al. 2010b), and UK (n=650; Niederer 




Cases (n=1830) Controls (n=2759) 
n Frequency n Frequency 
TT or TC 1770 0.97 2711 0.98 





Figure 6.3 Forest plot of the FCGR2B-232T-homozygosity and SLE meta-analysis. 
Meta-analysis of 1830 cases and 2759 controls from six case/control studies shows the strong 







6.2.4 Measuring FCGR3B CNV 
 
The prologue ratio test (PRT) is a robust methodology for estimating gene copy number within a 
copy number variable region (Armour et al. 2007). The PRT test has been used to measure copy 
number variation across several loci (Boteva et al. 2012; Fode et al. 2011; X.-J. Zhou et al. 2012), 
including FCGR3B (Morris et al. 2010; Niederer et al. 2010b).  
 
I used this robust assay to measure the FCGR3B copy number in the SLE cases and healthy controls 
(Methods Figure 2.3). 561 SLE cases and 708 healthy controls (Methods 2.1.2) were successfully 
genotyped for both the FCGR2B-I232T variant and FCGR3B CNV. The results are summarised by 
genotype in Table 6.3 and by allele in Table 6.4, and displayed in Figure 6.3. 
 
There was no difference in rs1050501 allelic frequency between the FCGR2B-I232T only data 
(n=1491; Table 6.1c) and the samples with both FCGR2B-I232T and FCGR3B CNV (n=1269; Table 
6.4a) for cases (χ2=0.043) or controls (χ2=0.046), indicating there was no rs1050501 genotype-














Table 6.3 FCGR2B rs1050501 genotyping results conditioned on FCGR3B copy number 
Genotype counts and frequencies for rs1050501 genotype groups, and combined TT and TC 
genotype groups are displayed for A) Total samples (not conditioned on FCGR3B copy number), B) 
Conditioned on two or more copies (no deletion) of FCGR3B. (C) Results conditioned on fewer than 
two copies of FCGR3B (at least one gene deletion). No significant difference in 232T-homozygosity 
was observed between case and control when genotype counts for combined groups (TT or TC) and 




Cases (n=561) Controls (n=708) 
Absolute Frequency Absolute Frequency 
TT 460 0.820 572 0.808 
TC 98 0.175 127 0.179 
TT or TC 558 0.995 699 0.987 





Cases (n=498) Controls (n=654) 
Absolute Frequency Absolute Frequency 
TT 407 0.817 523 0.800 
TC 88 0.177 122 0.187 
TT or TC 495 0.994 645 0.986 





Cases (n=63) Controls (n=54) 
Absolute Frequency Absolute Frequency 
TT 53 0.841 49 0.907 
TC 10 0.159 5 0.093 
TT or TC 63 1.00 54 1.00 




Table 6.4 FCGR2B rs1050501 allelic results conditioned on FCGR3B copy number 
Total rs1050501 allele counts and relative calculated frequencies are displayed for A) Total samples 
(not conditioned on FCGR3B copy number). B) Results conditioned on two or more copies (no 
deletion) of FCGR3B. (C) Results conditioned on fewer than two copies of FCGR3B (at least one gene 
deletion). N values refer to number of chromosomes. No significant difference was observed 
between case and control allele counts in any group: χ2=0.67 (p=0.41), 0.99 (p=0.32), and 1.06 




Cases (n=1122) Controls (n=1416) 
Absolute Frequency Absolute Frequency 
T 1018 0.907 1271 0.898 





Cases (n=996) Controls (n=1308) 
Absolute Frequency Absolute Frequency 
T 902 0.906 1168 0.893 





Cases (n=126) Controls (n=108) 
Absolute Frequency Absolute Frequency 
T 116 0.921 103 0.954 







6.2.5 FCGR2B-I232T and FCGR3B CN Interaction 
 
I combined the rs1050501 genotype groups TT (homozygous WT) and TC (heterozygous) for cases 
(n=498) and controls (n=654) without a FCGR3B deletion (CN≥2; Table 6.3b) to test for an association 
with minor allele (CC) homozygosity (232T-homozygosity). No significant difference between cases 
and controls was observed (p=0.25; Fisher’s exact test). Furthermore, I used a chi-squared test (2x2 
contingency table; df =1) to compare the allele counts of the rs1050501 variant between cases 
(n=498) and controls (n=654) without a FCGR3B deletion (CN≥2), as summarised in Table 6.4b. No 
difference was observed at the 95% significance level (χ2=0.99; p=0.32). 
 
I did not observe homozygosity of the rs1050501 minor allele (C) together with a reduced CN (<2) of 
FCGR3B in any individual from either the case or control cohort, therefore I could not test for a 232T-
homozygosity effect. This could be expected given the MAF of ~0.10 (therefore q2=0.01) and the 
small sample size within the FCGR3B <2 cohorts. The estimated ‘C’ allele frequency in cases with 
FCGR3B deletion is 0.079 (Table 6.4c). Therefore I should expect to observe 232T-homozygosity by 
increasing the sample size to n=160. However, the equivalent MAF in controls is 0.046 (Table 6.4c), 
and 232T-homozygosity would not be expected to be observed in fewer than 466 samples. 
 
I compared the allele counts of the rs1050501 variant between cases (n=63) and controls (n=54) 
with at least one FCGR3B deletion (CN<2), as summarised in Table 6.3c. Despite observing a higher 
frequency of the minor allele (C) in cases with reduced FCGR3B CN compared with controls (Figure 
6.4c), this did not reach significance at the 95% level (Fisher’s exact test p=0.42). An interaction 
between FCGR2B-I232T and FCGR3B-CNV was tested for by fitting an additive logistic regression 
model (SLE status as the outcome) using the statistical computing language R. The interaction term 








Figure 6.4 FCGR2B-I232T genotype and allele frequencies conditioned on FCGR3B copy number 
Frequencies in A) total samples irrespective of FCGR3B copy number, B) samples conditioned on ≥2 
copies FCGR3B and C) samples conditioned on <2 copies FCGR3B. No significant difference between 
cases and controls was observed in 232T-homozygosity (p=0.25 Fisher’s exact test) or allele 




















































































































The paradigm of ‘missing heritability’ in recent years has focused on as-of-yet unidentified genetic 
variants that, once identified, are expected to increase the amount of heritability of complex 
diseases explained by additive genetic variation. However, this paradigm assumes an additive model 
of contribution for each genetic variant, both known and unknown (Zuk et al. 2012). Without fully 
exploring the possibility of epistasis between associated genetic variants, whereby the combined 
effect of two risk factors is greater than the sum of the effects of the individual variants, we may be 
underestimating the amount of heritability explained (Eichler et al. 2010). In which case, at least part 
of what is currently considered as ‘missing heritability’ could in fact be ‘phantom heritability’ due to 
the assumption that the heritability of complex diseases is largely additive (Zuk et al. 2012). Indeed, 
gene-gene interactions between associated SNPs in SLE have been successfully identified in recent 
years in European and Chinese populations, as discussed in section 1.2.4  (X. Zhou et al. 2012; 
Hughes et al. 2012; Leng et al. 2012; Zuo et al. 2014). 
 
The FCGR locus is of particular interest in this instance following the recent identification of 
ectopically expressed CD32b on NK cells as a result of the FCGR3B gene deletion (Mueller et al. 
2013). This molecular peculiarity presents a fascinating a priori hypothesis of potential genetic 
interaction. Additionally, perhaps the true effect size of the FCGR2B-232T association with SLE is 
underestimated without the consideration of FCGR3B CNV. That is, the under-functioning CD32b-
232T variant may also contribute to SLE risk when ectopically expressed on NK cells, as has been 
demonstrated with B cells and macrophages (Floto et al. 2005; Kono et al. 2005). The ectopic 
expression of CD32b does not abolish its B cell expression (Mueller et al. 2013). Such an under-
functioning effect on an additional cell type may lead to an increased effect size when considered 
together with reduced FCGR3B CN. In the absence of this FCGR3B CNV consideration, studies could 
potentially be underestimating the contribution of FCGR2B-232T to SLE susceptibility. 
 
Reduced CN at FCGR3B, which is among the strongest genetic risk factors for SLE (OR=1.59), has 
been shown to be correlated with reduced CD16b expression on and immune complex uptake by 
neutrophils – the only cell type on which this receptor is expressed (Willcocks et al. 2008; Morris et 
al. 2010). However, the ectopic expression of FCGR2B, a direct product of a FCGR3B gene deletion, 
may also contribute to the functional explanation behind this robust disease association.  
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Evidence exists that when expressed on NK cells, FCGR2B maintains its inhibitory function (van der 
Heijden et al. 2012). Although, the functional effect of the I232T variant on NK cells has yet to be 
explored. I hoped this study would provide further evidence of function: an observed genetic 
interaction would suggest a further contribution from the FCGR2B-I232T variant to SLE risk via 
ectopic expression on NK cells. I observed a trend towards reduced MAF in controls (0.046) 
compared with cases (0.079), which suggest CD32b-232T could also be deleterious when ectopically 
expressed on NK cells.  
 
The hypothesis at the heart of this study is one of cis interaction. Therefore not knowing which 
rs1050501 allele is in phase with the FCGR3B deletion in I232T heterozygotes is problematic. By 
extracting mRNA from NK cells and genotyping rs1050501 using cDNA, it would be possible to be 
confident in the phase. Genotyping would essentially be ‘haploid’ with respect to FCGR2B as its 
expression in NK cells will be expressed from one chromosome only, allowing confident haplotype 
phasing (Mueller et al. 2013). 
 
I did not observe an association between FCGR2B-232T homozygosity and SLE, as previously 
reported in European cohorts (Niederer et al. 2010b; Willcocks et al. 2010). However, combining my 
data with previously published genotypes yielded a significant association of 232T-homozygosity and 
SLE (Figure 6.3). I am confident in my genotyping of the rs1050501 SNPs as I did not see a deviation 
from HWE (χ2=0.71) and neither forward nor reverse primers used in this assay contain any known 
SNPs as observed using UCSC genome browser. The SLE cases used in this study were not selected 
for any subphenotypes or for disease severity. It is perhaps possible that such differences in the SLE 
cohorts between studies contribute to the power to detect associations. 
 
Studies in East Asian cohorts have yielded consistent results of FCGR2B-232T association. This is 
likely to be due to increased power due to the elevated MAF in these populations (MAF=0.22-0.25), 
which is possibly driven by positive selective pressure due to its observed protective effect against 
the progression of severe malaria following infection (OR=0.5), which is strongly associated with 
childhood mortality (Clatworthy et al. 2007). The same protective effect, as well as SLE susceptibility, 
from the FCGR2B-232T variant has also been shown in a Kenyan cohort (Willcocks et al. 2010). Once 
again, possibly due to positive selection pressures, there is an observed elevated MAF in the Kenyan 
population (0.25) compared with Europeans (Willcocks et al. 2010). The frequency of the FCGR3B 
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deletion is also higher in these populations (Niederer et al. 2010b). Interestingly, the elevated 
frequencies of FCGR3B deletion is thought to be another example of positive selection pressures as a 
result of infectious agents (Machado et al. 2012). Together, the higher frequencies of both SLE 
susceptibility variants of the FCGR locus in these populations are likely to provide more adequate 
power to detect an interaction. 
 
The trend toward increases in minor allele frequency in cases (0.079) compared with controls (0.046) 
within individuals with an FCGR3B deletion suggests it may be possible to detect a genetic 
interaction with an increased sample size in an European cohort, or by conducting this study with 
cohorts known to have higher MAFs. An earlier study also observed a trend toward an interaction  in 
an European cohort (Niederer et al. 2010b). A meta-analysis could prove fruitful in this instance, as 
with the 232T association, in Europeans. 
 
Given the known ectopic expression of CD32b on NK cells due to the FCGR3B deletion, this issue is 
worth pursuing (Mueller et al. 2013). With individual ORs approaching 2, both FCGR variants 
considered here are among the strongest risk factors for SLE. However, exploring this putative 













Chapter 7: Conclusions 
 
7.1 Summary of findings 
 
The results of the work presented in this thesis, which I believe to be novel contributions to the field, 
can be summarised as follows: 
 
 The SLE-associated R77H variant in CD11b, encoded by rs1143679 in ITGAM, does not affect 
expression of CR3, under resting nor activated states, on the cell surface of monocytes and 
neutrophils from healthy volunteers of European ancestry. 
 Two case-specific non-synonymous rare variants in ITGAM, F941V and G1145S, impair CR3-
mediated phagocytosis of iC3b coated targets in vitro. 
 Two non-synonymous polymorphism within ITGAM, M441T (rs11861251) and A858V 
(rs1143683), do not affect phagocytosis in the same in vitro model, reducing the evidence of 
a secondary SLE association with the latter. 
 The small-molecule CR3 agonist, LA1, reduces cytokine and chemokines production by 
monokine-activated NK cells, and inhibits IL-15-mediated STAT5 phosphorylation. 
 An increased frequency of FCGR2B-I232 (WT) alleles is seen in a control cohort conditioned 
on FCGR3B gene deletion, compared with SLE cases. This suggests the possibility of a genetic 
interaction between the two SLE-associated variants, which may contribute further to 
disease risk. 
 
There are, of course, some limitations to these results, and conclusions could be aided by further 








7.2 Limitations and future work 
 
7.2.1 Rare Variants in ITGAM 
 
In Chapter 4 I demonstrated that two newly identified case-specific non-synonymous ITGAM rare 
variants, F941V and G1145S, impair CR3-mediated phagocytosis of iC3b coated targets in vitro. I 
believe the identification of case-specific, functionally deleterious rare variants within ITGAM adds 
further support to the role of CR3 in SLE pathogenesis.  
 
Although it has been suggested that defective phagocytosis is the primary cause of the R77H 
association (Fossati-Jimack et al. 2013), R77H has been demonstrated to affect many other CR3 
functions (MacPherson et al. 2011).  Unfortunately, the rarity of the two novel variants, F941V and 
G1145S, meant that ex vivo studies were not feasible. Therefore, my analysis of their functional 
impact was limited to the availability of in vitro models. Although I can conclude that neither affects 
iC3b-binding, and both affect phagocytosis, it would be of great interest to ascertain their effects on 
other CR3 functions. Particularly as the F941V variant had an even greater impact (61% reduction) 
on phagocytosis than R77H (31%), it is possible that other functions are more dramatically affected 
too.  
 
In addition, the minor allele of G1145S is in phase with the minor allele of P1146S on the 
chromosome. A recent study, published after the completion of my work, suggests P1146S also 
effects CR3 function on neutrophils (Y. Zhou et al. 2013). The phenomenon of an additive functional 
effect of both rare and common variants within the same polypeptide molecule is of particular 
interest when considering the contribution of rare variants to complex disease susceptibility. It 
would be possible to model this by introducing additional variants by site-directed mutagenesis to 
the CD11b plasmids. It would have been very interesting to introduce the P1146S to the pcDNA3.1(-
)-ITGAM(G1145S) plasmid and measure the impact of these two sequential missense variants on 
iC3b-dependent phagocytosis. Following the evidence presented by Zhou and colleagues (Y. Zhou et 
al. 2013), I would suspect that an even greater reduction in phagocytic function would be seen. 
Additionally, given the location of amino acids 1145 and 1146 in the short cytoplasmic tail of CD11b, 
it is possible that, in addition to the ‘outside-in’ signalling effects measured by the phagocytic assay, 
an effect on ‘inside-out’ signalling would also been seen. Of course, a suitable in vitro model, which 
is hitherto unavailable, would be needed to measure such functional consequences. 
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The study by Zhou and colleagues also reports diminished phagocytosis of IgG-coated targets by 
both 77H/A858/P1146 and R77/858V/1146S neutrophils (Y. Zhou et al. 2013), due to the disrupted 
cooperation between CR3 and CD16b (Krauss et al. 1994). This is of particular interest to SLE, 
suggesting variants within ITGAM may affect the ability of neutrophils to phagocytose immune 
complexes as well as iC3b-coated targets (such as apoptotic cells). It would also be of interest to 
explore whether the rare variants, particularly F941V due to its close proximity to the β-glucan 
domain on CD11b, also affect this cooperation.  
 
7.2.2 Effects of LA1 on CR3 functions 
 
In addition to aiding our understanding of complex pathologies of disease, genetic studies may also 
provide avenues of directed therapies. Genetic analyses have highlighted ITGAM polymorphisms as 
important in disease susceptibility, and functional studies have confirmed the R77H-mediated 
impairments to CR3 function (Nath et al. 2008; MacPherson et al. 2011). A high-throughput 
screening cell-adhesion assay was used to identify LA1, a novel agonists of CR3, discussed in detail in 
Chapter 5 (Faridi et al. 2009). The therapeutic potential, then, for LA1 to target this under-
functioning in inflammatory disease is a great example of translational research (Maiguel et al. 
2011). In Chapter 5 I demonstrate that LA1 acts by inhibiting IL-15-mediated STAT5 phosphorylation, 
resulting in reduced levels of cytokine and chemokines production. However, there are a number of 
potential avenues of future work in order to fully conclude my results, as discussed in section 5.3, 
which can be summarised as follows: 
 
 Increase the sample size in order to reduce variability in pSTAT3 fold-change following  IL-12 
and IL-15 activation to confirm there is indeed no LA1 effect on STAT3 tyrosine 
phosphorylation 
 Survey the effects of LA1 on the IL-18Rβ signalling cascade: MyD88 recruitment, IRAK 
phosphorylation, and NF-κB translocation 
 Measure IL-18Rβ expression to support the notion that LA1 does not affect the STAT4-
mediated induction of its expression 
 Survey the effects of LA1 on other cytokine receptor signalling pathways, in particular those 
containing the common γc and IL-2Rβ 
 Determine if LA1 effects harbour STAT5A or STAT5B specificity 
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Furthermore, it is of paramount importance to investigate the effects of LA1 on other CR3-mediated 
functions. In contradiction to a previous study whereby R77H-heterozygosity was enough to disrupt 
the inhibitory functions of LA1 pre-treatment on TLR-activated monocytes (Reed et al. 2013), the 
R77H genotype did not appear to affect the ability of LA1 to reduce NK cell cytokine/chemokines 
production, as demonstrated by the work of Dr Ben Rhodes (manuscript under review). This is a very 
important observation in the potential of LA1 as an SLE treatment, as the MAF of rs1143679 (R77H) 
is ≈0.15-0.2 in SLE cases across multiple ethnicities (S. Han et al. 2009). It would therefore be of 
pivotal importance to further explore the possibility of the genotype-dependent differential effects 
of LA1 on CR3 function. As previously discussed, one of the key R77H-mediated impairments is 
under-functioning of CR3 phagocytosis (Fossati-Jimack et al. 2013), and moreover the ‘waste-
disposal hypothesis’ is a key disease paradigm in SLE (Herrmann et al. 1998). LA1 has been 
demonstrated to stimulated phagocytosis of iC3b coated sheep red blood cells by CD11b/CD18 
transfected K562 cells (Maiguel et al. 2011). It would be of great interest to determine whether LA1 
is able to augment the impaired phagocytosis observed with 77H-expressing COS-7 cells (Rhodes et 
al. 2012), using the same in vitro model as applied to the functional study of ITGAM rare variants in 
Chapter 4.  
 
7.2.3 FCGR interaction 
 
In Chapter 6 of this thesis I explored the possibility of a genetic interaction between two SLE-
associated variants within the FCGR locus. In addition to FCGR3B CNV (OR=1.59) and FCGR2B-232T 
homozygosity (OR=1.73) being among the strongest risk factors for SLE, it has been demonstrated 
that FCGR3B gene deletion results in ectopic expression of CD32b on NK cells (Mueller et al. 2013). It 
is possible, then, that part of the genetic effect of reduced FCGR3B copy number is explained by this 
ectopic expression. Although I observed increased frequency of FCGR2B-I232 (WT) alleles in a 
control cohort conditioned on FCGR3B gene deletion, compared with SLE cases, the size of my study 
was under-powered to detect a significant difference given the relatively low MAFs of both variants 
in European populations (Willcocks et al. 2010). Additionally, I did not observe 232T-homozygosity 
together with FCGR3B deletion, and the association of rs1050501 association is only seen in 232T-
homozygosity (Kyogoku et al. 2002).  
 
However, I believe the trend observed in my data suggests that it is worthwhile to pursue this 
putative interaction using larger cohorts of European ancestry. Additionally, conducting a genetic 
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interaction analysis with samples from South East Asian or East African populations, which have 
elevated rs1050501 MAFs (Clatworthy et al. 2007) and increased frequency of FCGR3B CNV 
(Niederer et al. 2010b) thought to be due to selective pressures, may be fruitful. There are existing 
data suggesting allele frequency differences affect the ability to replicate interactions between 
populations (X. Zhou et al. 2012) 
 
Given the vast amount of genetic variants now known to be associated with SLE, hypothesis-free 
searches for interactions are likely to be hindered by multiple-testing restrictions. However, using 
functional knowledge to develop a priori hypotheses of interactions is likely to be more fruitful and 
informative (Sun and Kardia 2010). For instance, there has long been in vitro evidence that CR3 
facilitates CD16b-mediated phagocytosis (Krauss et al. 1994), and that the CR3 lectin-like domain is a 
binding site for sCD16 (Galon et al. 1996). Recently, functional evidence suggests R77H impairs 
neutrophil phagocytosis of IgG-coated targets presumably through the impaired interaction between 
CR3 and CD16b (Y. Zhou et al. 2013). Known protein interactions could therefore aid our search for 
informative genetic interactions, and increase our understanding of the genetic variance 
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Appendix A: PCR Reaction Compositions and Calculations 
 
Qiagen PCR Buffer and Promega dNTPs were used in all reactions, unless otherwise stated 
 







PCR Buffer  10X 1.0 0.5X 
dNTPs  2.5mM 1.0 0.25mM 
Forward Primer 5’- CACCATGCCCAGCTAATTAAA 10µM 0.5 0.5µM 
Reverse Primer 5’- CTCCTCCCCACCCAGAGT 10µM 0.5 0.5µM 
Hot Star Taq Polymerase 5U/µl 0.1 0.5U 
ddH2O - 4.9 - 
DNA 20ng/µl 2.0 2.0ng/µl 
Total - 10.0 - 
 
 
2. ITGAM Novel Variant Confirmation PCR 
Reagent Concentration (various) Volume (µl) Final concentration 
PCR Buffer 10X 2.0 1X 
dNTPs  2.5mM 2.0 0.25mM 
Forward Primer* 10µM 1.0 0.5µM 
Reverse Primer* 10µM 1.0 0.5µM 
Hot Star Taq Polymerase 5U/µl 0.2 1.0U 
ddH2O - 4.9 - 
DNA 10ng/µl 3.0 1.5ng/µl 
Total - 20.0 - 





3. SSP-PCR F941V 
Reagent Concentration (various) Volume (µl) Final concentration 
PCR Buffer 10X 1.0 1X 
dNTPs  2.5mM 1.0 0.25mM 
Outer Forward* 10µM 0.5 0.5µM 
Outer Reverse* 10µM 0.5 0.5µM 
Inner Forward* 10µM 0.5 0.5µM 
Inner Reverse* 10µM 0.5 0.5µM 
Hot Star Taq Polymerase 5U/µl 0.1 0.5U 
ddH2O - 4.9 - 
DNA 20ng/µl 1.0 2ng/µl 
Total - 10.0 - 
*See Methods Table 2.2 for primer sequences 
 
 
4. ITGAM Site-directed mutagenesis 
4.1. Primer Calculations 
4.1.1. Amount of primer in ρmoles needed for 125ng of primer: 
 
 
                        
     
                              
        
 
 
4.1.2. Volume of primer needed for site-directed mutagenesis reaction: 
 
             
               









4.2. Summary of used primers 
 
Primer Sequence 5’ – 3’ Length (b) Amount (ρm) Volume (µl) 
M441T F gcagaacactggcacgtgggagtccaacg 
 
29 13.06 1.31 
M441T R cgttggactcccacgtgccagtgttctgc 
 
29 13.06 1.31 
A858V F ccgaagtgtctggggtcttgaagagcaccag 
 
31 12.22 1.22 
A858V R ctggtgctcttcaagaccccagacacttcgg 
 
31 12.22 1.22 
F941V F tctccactaaatatctcaacgtcacggcctcagagaat 
 
38 10.00 1.00 
F941V R attctctgaggccgtgacgttgagatatttagtggaga 
 
38 10.00 1.00 
G1145S F atgagtgaagggagtcccccggggg 
 
25 15.15 1.52 
G1145S R cccccgggggactcccttcactcat 
 
25 15.15 1.52 
 
 
4.3. PCR reaction composition 
Reagent Concentration (various) Volume (µl) Final concentration 
Reaction Buffer 10x 5.0 1x 
pcDNA3.1-CD11b 10ng/µl 1.0 0.2ng/µl 
Forward primer* 10ρmoles/µl Various** 2.5ng/µl 
Reverse primer* 10ρmoles/µl Various** 2.5ng/µl 
dNTP mix  1.0  
Quik Solution  3.0  
ddH2O - Various*** - 
Pfu Ultra High Fidelity Polymerase  1µl  
Total - 50.0 - 
*See primer sequences in A4.2 
**See equations A4.1.1 and A4.1.2 
***          ddH2O       -     –                                              
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SequalPrep Reaction Buffer (with dNTPs) 10X 1.0 1X 
Enhancer A 10X 0.5 0.5X 
DMSO - 0.2 - 
Forward Primer 5’-CCTCACCTGGAGTTCCAGGAGGGAG 10µM 0.5 0.5µM 
Reverse Primer 5’-GCTTGGGTGGCCCCTGGTTCTCA 10µM 0.5 0.5µM 
SequalPrep Long Polymerase™ 5U/µl 0.18 0.9U 
ddH2O - 6.62 - 
DNA 20ng/µl 0.5 2.4ng/µl 


















6. FCGR3 CNV 
6.1. Paralogue Ratio Test (PRT) 
 







low dNTPs PRT Mix* 10X 1.0 1X 
Forward Primer 5’-ATGATCTGGCCCTGAAACTC 10µM 0.5 0.5µM 
Reverse 5’-
[HEX/FAM]TGAGTTCAAGAAAGCAGTTTGG 
10µM 0.5 0.5µM 
Taq Polymerase 5U/µl 0.1 0.5U 
ddH2O - 6.9 - 
DNA 20ng/µl 1.0 2ng/µl 
Total - 10.0 - 












low dNTPs PRT Mix* 10X 1.0  
A Forward 5’TTTTGCAGTGGACACAGGAC 10µM 0.5 0.5µM 
A Reverse 5’-[VIC]GGGTTGCAAATCCAGAGAAA 10µM 0.5 0.5µM 
Taq Polymerase 5U/µl 0.1 0.5U 
ddH2O - 6.9 - 
DNA 20ng/µl 1.0 2ng/µl 
Total - 10.0 - 





Appendix B: Thermocycler Conditions 
 
1. ITGAM promoter sequencing 
PCR Step Temperature (°C) Time (minutes) 
Enzyme Activation 95.0 15.0 
 
Denaturation 94.0 0.5  
30 cycles Annealing 58.0 0.5 
Extension 72.0 1.0 
 
Final Extension 72.0 10.0 
 
 
2. ITGAM Novel Variant Confirmation PCR 
PCR Step Temperature (°C) Time (minutes) 
Enzyme Activation 95.0 15.0 
 
Denaturation 94.0 0.5  
30 cycles Annealing Various* 0.5 
Extension 72.0 0.5 
 
Final Extension 72.0 10.0 










3. SSP-PCR F941V 
PCR Step Temperature (°C) Time (minutes) 
Enzyme Activation 95.0 15.0 
 
Denaturation 94.0 0.5  
30 cycles Annealing 56.9 0.5 
Extension 72.0 0.5 
 
Final Extension 72.0 10.0 
 
 
4. ITGAM Site-directed Mutagenesis 
PCR Step Temperature (°C) Time (minutes) 
Enzyme Activation 95.0 1.0 
 
Denaturation 94.0 0.83  
18 cycles Annealing 60.0 0.83 
Extension 72.0 9.0 
 













5. FCGR2B-I232T genotyping by LR PCR 
PCR Step Temperature (°C) Time (seconds) 
Enzyme Activation 94.0 120 
 
Denaturation 94.0 10  
10 cycles Annealing 66.0 30 
Extension 68.0 180 
 
Denaturation 94.0 10 25 cycles 
Annealing 66.0 30 
Extension 68 180 +20sec/cycle 





















6. FCGR3 CNV 
 
6.1. Paralogue Ratio Test 
PCR Step Temperature (°C) Time (minutes) 
Denaturation 95.0 0.5 
Annealing 56.0 0.5 30 cycles 
Extension 70.0 3.0 
 
Annealing 56.0 1.0 
Final Extension 70.0 20.0 
 
 
6.2. Restriction Enzyme Digest Variant Ratio (REDVR) 
PCR Step Temperature (°C) Time (minutes) 
Denaturation 95.0 0.5 
Annealing 53.0 0.5 30 cycles 
Extension 70.0 3.0 
 
Annealing 53.0 1.0 












Appendix C: Recipes 
 
1. Precipitation Buffer 
Reagent Stock Concentration Volume Used (μl) 
Sodium Acetate 3M (pH6) 75 
H2O n/a 362.5 
Ethanol 95% 1562.5 
 Total 2000 
 
 
2. Low dNTP 10x PCR Mix 
Reagent Stock Concentration Volume Used (μL) Final Concentration 
TrisHCl pH8.8 2M 500 500mM 
Ammonium Sulphate 1M 250 125mM 
MgCl2 1M 28 14mM 
2-mercaptoethanol 100% 10.5 75mM 
dATP 100mM 40 2mM 
dCTP 100mM 40 2mM 
dGTP 100mM 40 2mM 
dTTP 100mM 40 2mM 
BSA 10mg/ml 250 1.25mg/ml 
Water  n/a 800  n/a 
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